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Macrophages (Mφ) have previously been implicated in both acute 
and chronic renal allograft rejection however the mechanisms 
remain unclear. In this thesis I set out to explore the effect of the 
Mφ on the endothelium in the context of renal graft rejection. 
Initial studies focussed upon human renal allograft tissue from 
transplant nephrectomies performed because of chronic allograft 
nephropathy (CAN). Immunostaining was carried out on these 
tissues (n=29) and control kidney tissue obtained from 
nephrectomies performed for renal cell carcinoma (n=19). An 
increased interstitial Mφ infiltrate was found compared to control 
tissue. Immunostaining for the T cell marker CD3 and the B cell 
marker CD20 demonstrated that both lymphocyte populations were 
present in the CAN tissue with almost negligible numbers seen in 
control tissue. Previous work in the group had demonstrated a 
reduced number of CD31 positive peritubular capillaries in the 
tissues used in these studies. In the work undertaken in this thesis, 
additional analysis was performed to study lymphatic vessels. 
Immunostaining of control tissue with the lymphatic endothelial cell 
(LEC) marker podoplanin demonstrated a normal distribution of 
lymphatic vessels around large interlobular arteries. CAN tissue, 
however, exhibited an increased lymphatic density with lymphatic 
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vessels evident within the interstitium; a finding verified with two 
additional LEC markers (LYVE-1 and VEGFR-3). 
 
Further investigations examined possible mediators that could be 
responsible for the reduced microvascular peritubular capillary 
network and increased lymphatic vessels present in tissues affected 
by CAN. Previous work had implicated nitric oxide (NO) generated 
by the enzyme inducible nitric oxide synthase (iNOS) in cardiac 
allograft rejection. Double immunolabelling for iNOS and the Mφ 
marker CD68 revealed evidence of Mφ expression of iNOS. No 
obvious reduction in vascular endothelial growth factor (VEGF)-A 
was evident although marked expression of VEGF-A was found in 
CD20 positive B cells within CAN tissue. Occasional interstitial cells 
expressed the lymphangiogenic growth factor VEGF-C, with double 
labelling studies indicating occasional CD68 +ve Mø that were 
positive for VEGF-C.  
 
In vitro studies were undertaken to dissect the interaction between 
Mø and microvascular endothelial cells (MCEC-1) using well 
established in vitro co-culture techniques. Co-culture of cytokine 
activated bone marrow derived Mø with MCEC-1 cells (a murine 
cardiac microvascular endothelial cell line) resulted in increasing 
levels of MCEC-1 apoptosis and a reduced cell number over a 24-
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hour time course. Non-activated Mø or cytokines alone were not 
cytotoxic. Co-cultures were performed in the presence of L-N-
imino-ethyl lysine (L-Nil), a specific inhibitor of iNOS (control D-N6- 
(1-iminoethyl)-lysine (D-Nil)). L-Nil significantly inhibited MCEC-1 
apoptosis and preserved cell number implicating a major role for 
NO in Mø-mediated MCEC-1 death. Importantly, L-Nil treatment did 
not affect TNFα production by cytokines suggesting that TNFα is 
not involved in MCEC-1 death in this in vitro experimental system. 
 
Experiments were then undertaken involving the depletion of Mø in 
a murine model of acute renal allograft rejection. Renal transplants 
were performed between donor Balb/c mice and either FVB/N 
CD11b-DTR mice transgenic for the diphtheria toxin receptor (DTR) 
under the CD11b promoter or control non-transgenic FVB/N mice. 
Diphtheria toxin (DT) was administered on days 3 and 5 to induce 
Mø depletion and mice sacrificed at day 7. Isograft controls were 
also performed between FVB/N mice. Murine allografts exhibited 
marked interstitial F4/80 positive Mø infiltration with expression of 
iNOS in the allografts. There was significant loss of peritubular 
capillaries (PTC) in allografts compared to isografts, indicating 
microvascular injury. DT treated CD11b-DTR mice exhibited 75% 
reduction in Mø infiltration and this was associated with dramatic 
microvascular protection. B and T cells were not evident in the 
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isograft but significant accumulation of B and T cells was present in 
the allograft and not affect by Mø depletion. Interestingly, there 
was an increase in the number of podoplanin positive lymphatic 
vessels in the allograft compared to the isograft, which was 
significantly inhibited following Mø depletion. 
 
The final area of study focussed upon attempts to isolate lymphatic 
endothelial cells in vitro. Two types of vascular cells (HUVECs and 
HDMECs) were analysed by flow cytometry for LEC markers and 
immunofluorescence to phenotype the cells. Magnetic bead sorting 
was then undertaken to isolate discrete populations of endothelial 
cells expressing LEC markers.  
 
The murine studies reinforce the cytotoxic potential of Mø and 
supports a role for Mø in the deleterious rarefaction of 
microvascular interstitial vessels with resultant tissue hypoxia and 
ischaemia. Furthermore, these data support the involvement of Mø 
in the interstitial lymphangiogenesis that may occur in renal 
allografts. Furthermore, the study of human allograft tissue 
indicates that microvascular rarefaction and an increase in 
intrarenal lymphatic vessels occurs in human disease. Lastly, Mø 
expression of iNOS and VEGF-C suggests that Mø are involved in 







Dedicated to my husband Nick for his continuing 
encouragement, my mum for her enthusiasm, and 
in memory of my dad who will always be an 






I must firstly thank my supervisors Jeremy Hughes and Lorna 
Marson for their energy, ideas and patience. I had two fantastic 
supervisors as well as gaining two good friends, thank you. 
I would like to thank Professor John Savill for allowing me to 
become part of his research group and giving me his wise thoughts 
at many lab meetings. 
A special thanks to all my colleagues who kept me going through 
out my research time. Firstly Tiina Kipari without her much of my 
research would not have been possible, Dave Ferenbach, David 
Walbaum and Kris Houlberg who were always there to answer my 
questions and queries. Thank you to Shonna Johnstone for her help 
using Flow cytometry and confocal microscopy, and a big thank 
you to Professor Sarah Howie and Anne Grant for their advise on 
immunohistochemistry. 
I must also say thank you to the Medical Research Council (MRC) 
for funding my work through an MRC clinical training fellowship. 
Lastly thank you to my family and friends whose continuing love 





I, Anya Adair, declare that this thesis was composed myself and 
the work contained herein is my own and was done by myself with 
the technical help of people I have acknowledged in the 
appropriate section, and this work has not been submitted for any 






















Table of Contents ix 
Index of Figures ..xvii 
Index of Tables .xxi 
Abbreviations xxii 
 
Chapter 1: Introduction 
1.1 Kidney transplantation .......................................................2 
1.1.1 Background....................................................................2 
1.1.2 Acute Rejection ..............................................................4 
1.1.3 Chronic allograft nephropathy (CAN) .................................7 
1.1.4 Immunosuppressants and the treatment of CAN............... 12 
1.2 Macrophages .................................................................. 15 
1.2.1 Background.................................................................. 15 
1.2.2 Macrophage infiltration correlates closely to cell  apoptosis in 
renal disease........................................................................ 17 
 x
1.2.3 Macrophage infiltration associated with increased risk of 
acute and chronic allograft rejection........................................ 17 
1.3 Apoptosis ....................................................................... 19 
1.3.1 Background.................................................................. 19 
1.3.2 Mediators of Apoptosis .................................................. 20 
1.3.2.1 Nitric Oxide ............................................................... 20 
1.3.2.2 TNFα and Fas-ligand................................................... 23 
1.4 Lymphocytes .................................................................. 25 
1.4.1 Background. ................................................................ 25 
1.4.2 T cells ......................................................................... 25 
1.4.3 B cells ......................................................................... 28 
1.4.3.1 Antibodies and antigen presentation............................. 28 
1.4.3.2 The B cell and lymphangiogenesis ................................ 29 
1.5 The Endothelium ............................................................. 33 
1.5.1 Background.................................................................. 33 
1.5.2 Vascular endothelial growth factor family and their   
receptors. ............................................................................ 33 
1.5.3 Identification and phenotyping of lymphatic endothelial cells 
(LECs) vs vascular endothelial cells (VECs)............................... 38 
1.5.4 Vascular endothelial cell proliferation and rarefaction ........ 44 
1.5.5 Lymphangiogenesis....................................................... 46 
1.5.5.1 Background............................................................... 46 
1.5.5.2 Lymphangiogenesis and the Mφ ................................... 46 
 xi
1.5.5.3 Where do these new lymphatics come from? ................. 47 
1.5.5.4 What is the role of these new lymphatic vessels? ........... 48 
1.6 Aims & Hypothesis........................................................... 50 
 
Chapter 2:  Materials and Methods 
2.1 Immunohistochemistry and immunofluoresence .................. 53 
2.1.1 Tissue specimens.......................................................... 53 
2.1.1.1 Human: .................................................................... 53 
2.1.1.2 Murine :.................................................................... 53 
2.1.2 Immunohistochemistry.................................................. 59 
2.1.2.1 Method for Immunohistochemistry (IHC) ...................... 59 
2.1.2.2 Double labelling :....................................................... 63 
2.1.2.3 IHC analysis of tissue sections..................................... 64 
2.1.3 Immunofluorescence (IF)............................................... 68 
2.1.3.1 Method for IF ............................................................ 68 
2.1.3.2 Microscopes used for IF studies ................................... 71 
2.2 Cell culture ..................................................................... 72 
2.2.1 General reagents .......................................................... 72 
2.2.2 Murine cardiac endothelial cell (MCEC-1) ......................... 72 
2.2.2.1 Description................................................................ 72 
2.2.2.2 MCEC-1 cell............................................................... 73 
2.2.2.3 Thawing and passaging cells ....................................... 73 
2.2.2.4 Freezing and storage of cells ....................................... 74 
 xii
2.2.3 Culture of primary bone marrow derived macrophages 
(BMDM) ............................................................................... 75 
2.2.3.1 Preparation BMDM ..................................................... 75 
2.2.3.2 Macrophage supernatant harvesting............................. 77 
2.2.4 Co-culture experiments ................................................. 78 
2.2.4.1 Direct co-culture between BMDM and MCEC-1 ............... 79 
2.2.4.2 Assessment of apoptotic cell retention in fixed co-cultures
.......................................................................................... 80 
2.2.4.3 Assessment of MCEC-1cell apoptosis and proliferation by 
fluorescent microscopy .......................................................... 81 
2.2.4.4 Video microscopy....................................................... 81 
2.3 Griess Assay ................................................................... 82 
2.3.1 Method: ...................................................................... 82 
2.4 Enzyme linked immunosorbent assay (ELISA) ..................... 83 
2.4.1 Method........................................................................ 83 
2.5 Flow Cytometric Analysis of Cells....................................... 85 
2.5.1 Fas Ligand expression by BMDM ..................................... 85 
2.6 Lymphatic endothelial cell identification & isolation .............. 86 
2.6.1 Cells examined............................................................. 86 
2.6.2 Method for passaging, freezing & thawing cells................. 86 
2.6.2.1 Passaging cells .......................................................... 86 
2.6.2.2 Freezing storage anf thawing of cells ............................ 88 
2.6.3 Methods for phenotyping cells ........................................ 89 
 xiii
2.6.3.1 Flow cytometry.......................................................... 89 
2.6.3.2 Immunofluorescence .................................................. 90 
2.6.3.3 Electron microscopy studies ........................................ 92 
2.6.4 Magnetic bead sorting of HDMEC cell line......................... 93 
2.7 Statistical analysis ........................................................... 94 
 
Chapter 3: Analysis of the Lymphatic and Vascular 
Endothelium in Human Chronic Allograft Nephropathy 
3.1 Introduction.................................................................... 96 
3.2 Patient Information.......................................................... 97 
3.3 Confirmation of endothelial staining in human tissue............ 99 
3.4 Upregulation of interstitial lymphatics is seen within CAN 
tissue. ............................................................................... 101 
3.5 Increased mononuclear cell infiltrate in CAN105 
3.6 iNOS expression seen in CAN tissue co-localised to macrophage 
infiltrate108 
3.7 Localisation of VEGF-A and -C expression.108 
3.8 Analysis of nephrectomy grafts with continued 
immunosuppression show comparable changes to results seen 
including all grafts............................................................... 114 
3.9 Summary & discussion ................................................... 116 
 xiv
 
Chapter 4: The Role of Nitric Oxide in Mφ mediated 
Endothelial Cell Apoptosis 
4.1 Introduction.................................................................. 120 
4.2 Co-cultures exhibit reduced endothelial cell mitosis that is 
independent of cytokine stimulation. ..................................... 121 
4.3 Cytokine activated co-cultures exhibit increased endothelial cell 
apoptosis ........................................................................... 124 
4.4 Cytokine activation of co-cultures results in a reduction of total 
number of MCEC-1 cells....................................................... 128 
4.5 Transferability of death signal ......................................... 130 
4.6 Video microscopy .......................................................... 132 
4.7 Mediators of apoptosis ................................................... 133 
4.7.1 Nitric oxide is implicated in this system ......................... 133 
4.7.2 TNFα production by activated macrophages is not inhibited by 
the addition of L-Nil............................................................. 138 
4.7.3 Fas-L is not expressed by the activated BMDM ............... 138 





Chapter 5: The Vascular and Lymphatic Endothelium in 
Experimental Murine Renal Transplantation 
5.1 Introduction.................................................................. 145 
5.2 Macrophage infiltration seen in allografts was reduced by 
diphtheria toxin injection ..................................................... 146 
5.3 T and B cell infiltration was not affected by DT injection ..... 149 
5.4 Reduction in microvascularity seen in murine allografts is 
inhibited by macrophage depletion........................................ 156 
5.5 Reduction in tubular iNOS expression and increased interstitial 
iNOS expression is seen in murine allografts. ......................... 159 
5.6 Urine nitrite concentrations are comparable pre and post 
transplantation and are unaffected by Mφ depletion................. 160 
5.7 Lymphatic vessels in murine transplanted renal tissue ....... 164 
5.8 Summary & discussion ................................................... 168 
 
Chapter 6: Lymphatic Phenotyping and Isolation in vitro 
6.1 Background .................................................................. 173 
6.2 Human umbilical vein endothelial cells (HUVECs) contain a 
small proportion of lymphatic endothelial cells. ....................... 174 
 xvi
6.3 Human dermal microvasular endothelial primary cells 
(HDMECS) are made up of lymphatic and vascular endothelial cell 
populations. ....................................................................... 177 
6.4 Human dermal microvasular endothelial cell Line (HDMECS)180 
6.5 Summary & discussion ................................................... 184 
 
Chapter 7: Discussion 
7.1 General Discussion ........................................................ 187 
7.2 Future work.197 
7.3 Clinical relevance and treatment options204 
References .......................................................................206 
 
Appendix 1: Published work resulting from work from this thesis 
Appendix 2: Attached DVD - co-culture video microscopy 
 
 xvii
                                 Index of Figures 
 
Figure 1- 1 Acute rejection is thought to occur via T cell activation        
and current immunosuppressants target this pathway ................6 
Figure 1- 2  T cell maturation (adapted from Immunology by Janis 
Kuby) .................................................................................. 27 
Figure 1- 3 The putative role of the B cell in lymphangiogenesis . 32 
Figure 2- 1 Murine model of renal transplantation.55  
Figure 2- 2 Murine transplants using CD11b-DTR mice transgenic  
for the Diphtheria toxin receptor (DTR) as the recipient ............. 58 
Figure 2- 3 Immunohistochemistry double labelling................... 63 
Figure 2- 4 Image J analysis of F4/80 stain. ............................. 67 
Figure 2- 5 Method for immunofluorescent staining ................... 68 
Figure 2- 6 Characterisation of BMDM using cytospin and Diff Quick 
staining of BMDM in suspension at day 7 maturation ................. 76 
Figure 2- 7 In vitro co-culture assay of interaction between murine 
BMDM and MCEC-1 cells. ....................................................... 78 
Figure 3- 1 Immunohistochemical staining of endothelial cells in 
human renal control tissue. 100 
Figure 3- 2 Staining of lymphatic endothelium in human renal 
tissue ................................................................................ 102 
Figure 3- 3 Lymphatic vessel containing CD68 +ve Mφ in CAN 
tissue ................................................................................ 103 
Figure 3- 4 Lymphatic vessels are found in the interstitium of 
human renal tissue in CAN..104 
Figure 3- 5 Interstitial infiltrate of Mφ, T cells and B cells are 
present in the CAN tissue..................................................... 106 
Figure 3- 6 Increase in interstitial Mφ infiltrate is seen in the CAN 
tissue compared to control kidney tissue.107 
Figure 3- 7 Interstitial CD68 positive Mφ express iNOS............. 109 
 xviii
Figure 3- 8 VEGF-C immunostaining of human kidney tissue .... 110 
Figure 3- 9  Immunohistochemical staining of VEGF-A on human 
kidney tissue ...................................................................... 111 
Figure 3- 10 VEGF-C expression by the inflammatory infiltrate in 
CAN tissue. ........................................................................ 112 
Figure 3- 11 VEGF-A expression by the inflammatory infiltrate in 
CAN tissue. ........................................................................ 113 
Figure 4- 1 Proliferating endothelial cells were evident in control 
co-culture wells. 122 
Figure 4- 2 Inhibition of endothelial cell proliferation is Mφ 
dependant but cytokine independent. .................................... 123 
Figure 4- 3 Apoptotic endothelial cells in activated co-cultures.. 125 
Figure 4- 4 Cytokine activated Mφ  induce MCEC-1 cell apoptosis.
........................................................................................ 126 
Figure 4- 5 Occasional phagocytosis of endothelial cells was evident 
in activated co-cultures........................................................ 127 
Figure 4- 6 Reduction in endothelial cell number is only seen in 
activated co-culture............................................................. 129 
Figure 4- 7 The Mφ  death signal is not transferable. ................ 131 
Figure 4- 8 Nitrite produced by activated Mφ is effectively inhibited 
by L-Nil.............................................................................. 135 
Figure 4- 9 Apoptosis was almost completely abolished with the 
addition of L-Nil but not D-nil. .............................................. 136 
Figure 4- 10 Endothelial cell number is preserved by addition of L-
Nil to activated co-cultures................................................... 137 
Figure 4- 11 L-Nil does not effect TNFα production by activated Mφ
........................................................................................ 139 




Figure 5- 1 Murine allografts exhibit increased Mφ infiltration which 
is reduced following DT treatment......................................... 147 
Figure 5- 2 Mφ ablation is achieved by injection of diphtheria toxin.
........................................................................................ 148 
Figure 5- 3 Allografts exhibit increased interstitial T cell infiltration, 
which is not reduced by DT treatment. .................................. 150 
Figure 5- 4 Diphtheria toxin mediated monocye Mφ ablation does 
not affect T cell infiltration in murine renal allograft tissue. ...... 151 
Figure 5- 5 Allografts exhibit increased interstitial B cell infiltration, 
which is not inhibited by DT treatment................................... 153 
Figure 5- 6 Diphtheria toxin mediated monocyte/Mφ ablation does 
not affect B cell infiltrate in murine renal allograft tissue.......... 154 
Figure 5- 7 Blood analysis of circulating mononuclear cells at day 7 
post transplant using flow cytometry. .................................... 155 
Figure 5- 8 Allograft exhibit a reduction in CD31 microvascularity 
which is preserved following DT mediated monocyte/Mφ ablation.
........................................................................................ 157 
Figure 5- 9 Diphtheria toxin mediated monocyte/Mφ ablation 
preserves microvasculature in murine renal allograft tissue...... 158 
Figure 5- 10 iNOS immunostaining on murine transplanted renal 
tissue. ............................................................................... 161 
Figure 5- 11 Allografts exhibit increased interstitial iNOS expression 
and reduced tubular expression of iNOS compared to isografts. 162 
Figure 5- 12 Urine nitrite concentration is not affected by Mφ 
depletion. .......................................................................... 163 
Figure 5- 13 Podoplanin positive vessels in murine transplanted 
renal tissue. ....................................................................... 165 
Figure 5- 14  The increased number of lymphatic venules evident in 
allografts is inhibited following Mφ depletion. .......................... 166 
 xx
Figure 5- 15 Mφ containing an ingested apoptotic cell within a 
podoplanin positive lymphatic vessel arrowed)........................ 167 
Figure 6- 1 Phenotyping HUVECs using flow cytometry ..175 
Figure 6- 2 Phenotyping HUVECs using immunofluorescence .... 176 
Figure 6- 3 Phenotyping HUDMECs (cell line) using flow cytometry
........................................................................................ 178 
Figure 6- 4 Phenotyping HUDMECs (primary cells) using 
immunofluorescence............................................................ 179 
Figure 6- 5 HDMECs were cultured following magnetic bead sorting 
for CD31+/podoplanin+ cells ................................................. 181 
Figure 6- 6 Phenotyping HDMECs (cell line) post magnetic bead 
sort using flow cytometry..................................................... 182 
Figure 6- 7 Electron microscopy of HUdMECs (cell line) after 
magnetic bead sorting for podoplanin+ cells ........................... 183 
 
 xxi
Index of Tables 
 
Table 1- 1. Vascular endothelial growth factor receptors ............ 34 
Table 1- 2 Vascular and lymphatic endothelial cell markers ........ 40 
Table 2-1 Antibodies used for immunohistochemical staining .61 
Table 2- 2 Antibodies used for IF ............................................ 70 
Table 2- 3: Antibodies used for phenotyping cells...................... 91 
Table 3- 1 Details of patients with CAN whose renal tissue was 
studied in this work. 98 
Table 3- 2  Comparison between patients with immunosuppression 





% : Percentage 
°C  : degrees Celsius 
A : Absorbance 
ABAM : antibiotic antimycotic 
APCs : Antigen presenting cells 
BMDM : bone marrow derived Mφ 
BSA : bovine serum albumin 
BW : body weight 
cAMP : cyclic adenosine monophosphate 
CAN : Chronic allograft nephropathy 
CLEVER-1 : Combined lymphatic endothelial and vascular 
endothelial receptor 
CNIs : Calcineurin inhibitors 
CO2  : carbon dioxide 
CSF-1 : colony stimulating factor 1 
DAB : diaminobenzidine 
DABCO : 1-4-diazabicyclo-2-2-2-octane  
DC : dendritic cell 
DMEM/F12  : dulbeccos modified eagle medium with F12  
DMSO : dimethylsulphoxide 
D-NIL : D-N6-(1-iminoethyl)-lysine  
DT : diphtheria toxin  
 xxiii
ECGF : Endothelial cell growth factor 
ECM : extracellular matrix 
EDTA : ethylenediaminetetraacetic acid 
EFG : epidermal growth factor 
eNOS : endothelial NOS 
EtOH : ethanol 
ESRF : End stage renal failure 
FACS : fluorescence-activated cell sorter 
FasL : fas ligand 
FCS : foetal calf serum 
FITC : fluorescein isothiocyanate 
H2O2 : hydrogen peroxide 
HBSS : hanks balanced salt solution  
Hpf : high power field 
HUVECs : Human umbilical vein endothelial cells 
HDMECs : Human dermal microvascular endothelial cells 
I/R : ischemia reperfusion  
ICAM-1 : intercellular adhesion molecule 1 
IFN-γ : inteferon gamma 
Ig : immunoglobulin  
IL : interleukin 
IMPDH : Inosine monophosphate dehydroenase 
iNOS : inducible NOS 
 xxiv
LEC : Lymphatic endothelial cell 
L-NIL : L-N-imino-ethyl lysine  
LPS : lipopolysaccaride 
MAC-1 : 
CD11b antigen (macrophage differentiation 
antigen) 
LYVE-1 : Lymphatic Vessel Endothelial Receptor 1 
MCP-1 : monocyte chemoattractant protein l 
MDCK : madin darby canine kidney 
Mφ : macrophage 
MHC : Major histocompatibility complex  
Min : minute 
MMF : mycophenolate mofetil 
mTOR : Mammalian target of rapamycin 
NaCl : sodium cloride 
NK cells : Natural killer cells 
NFKβ : nuclear factor-kappa B 
nNOS : neuronal NOS 
NO : niric oxide 
NO2- : nitrite 
NOS : NO synthase 
PBS : phosphate buffered saline 
PBS -/- : PBS without calcium and magnesium 
PECAM-1 : platelet endothelial cell adhesion molecule 1 
 xxv
PGs : prostaglandins 
PMN : neutrophil 
QOL : Quality of life 
RT : room temperature 
TBS : tris buffered saline 
Tc : cytotoxic T cell 
TGF-β : transforming growth factor beta  
Th : T helper cells 
TLRs : Toll like receptors 
TNF-α : tumour necrosis factor alpha  
TNFR : tumour necrosis factor receptor  
VSMCs : Vascular smooth muscle cells 
VCAM-1 : vascular cell adhesion molecule 1 
VEC : Vascular endothelial cell 
VEGF : Vascular endothelial cell growth factor 
VEGFR : Vascular endothelial cell growth factor receptor 
vs : Versus 
VWf : Von Willebrand factor 
WT : wild-type 









Chapter 1.  
 











1.1  Kidney transplantation 
1.1.1  Background 
The first kidney transplant was performed between identical twins in 
1954 (Tantravahi et al., 2006). Since then renal transplantation has 
become the treatment of choice for patients with end stage renal 
failure (ESRF) (Vathsala, 2005). It results in an increased life 
expectancy, and the overall risk of mortality is reduced by 80% at 
12 months following transplantation when compared to patients who 
remain on dialysis (McDonald and Russ, 2002). This significant 
survival benefit also holds true in the elderly patient (Oniscu et al., 
2004). In addition recipients experience a dramatic and all round 
improvement in quality of life (QOL) when compared to their dialysis 
dependent counterparts. They become more active and there is 
dramatic reduction in hospitalisation rates (Fiebiger et al., 2004; 
Nielens et al., 2001; Pietrabissa et al., 1992; Vathsala, 2005). 
With the ever-increasing number of patients with ESRF and the 
limited supply of donor kidneys for transplantation it is essential that 
every renal transplant be optimised to achieve long-term patient and 
allograft survival. In recent years acute rejection rates have 
improved with the introduction of new immunosuppressants and one 
year survival is now routinely >90% (Cohen et al., 2006). 
Unfortunately this has not translated into an increase in allograft life 
span or a reduction in late graft loss rates (Afzali et al., 2005; 
Vathsala, 2005; Vuillemin et al., 1997). Besides death of a patient 
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with a functioning graft the most common cause of late graft loss is 
Chronic Allograft Nephropathy (CAN). I am aware that the 
terminology has recently changed but for the purpose of this thesis I 
will continue to use this term as this was used at the start of my 
studies. CAN accounts for 50-80% of graft failure in surviving 
recipients and results in an annual graft loss rate of 3-5% (Afzali et 
al., 2005; Joosten et al., 2005; Pascual et al., 2002). It is also the 
leading cause of graft loss in paediatric recipients (Alexander et al., 
2006). CAN is the main cause of requiring return to dialysis and re 
listing following a transplant (Halloran et al., 1999). In this way it 
increases the burden on dialysis resources and adds to the ever-
increasing transplant waiting list.   
The two greatest dilemmas presently facing the renal transplant 
community are lack of organ availability and late graft loss. CAN is 
an irreversible process eventually resulting in return to dialysis and 
re transplantation and therefore poses a major problem in renal 
transplantation.  
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1.1.2 Acute Rejection 
The Major Histocompatibility Complex (MHC) antigens (or Human 
Leukocyte Antigens (HLA) in humans distinguish self from non-self.  
These MHC antigens expressed on donor cells act as targets to the 
recipient immune system and are responsible for initiating the 
rejection process. Acute rejection is primarily mediated through T 
cells. T cells recognise donor alloantigen in one of two ways and this 
stimulates the alloimmune response (fig 1-1). 
Direct alloantigen recognition: Donor antigen is presented on 
donor antigen presenting cells (APCs) to recipient T cells in lymphoid 
tissue. This appears to be important in the early rejection process 
where many donor APCs have accompanied the graft into the 
recipient. 
Indirect alloantigen recognition: Donor antigen is presented on 
recipient APCs to recipient T cells. This pathway may be important in 
maintaining the immune response. (Benichou et al., 1999; Martinez 
and Rosen, 2005; Tantravahi et al., 2006). The interaction between 
recipient T cells and donor antigens on APCs whether direct or 
indirect leads to T cell activation. T cell activation directly induces T 
cell proliferation and cytokine generation (importantly IL-2) leading 
to both humoral and cell mediated responses. This results in immune 
mediated allograft damage and ultimately acute rejection. (Fox and 
Harrison, 2000; Tantravahi et al., 2006). 
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The basis of immunosuppressive therapy is to inhibit activation of 
the immune system in response to donor MHC. Current 
immunosuppressive agents act by inhibiting T cell activation 
pathways either by disrupting IL-2 action or directly inhibiting cell 
proliferation. 
Prednisolone disrupts cytokine pathways associated with T cell 
activation, particularly those induced through NFκβ. Calcineurin 
inhibitors (CNIs) have been pivotal in reducing acute rejection rates. 
The first CNI, cyclosporine was introduced into clinical practice in the 
1980s. Tacrolimus followed and was first used in the transplant 
setting in 1990. They act by preventing transcription of the IL-2 
gene. Unfortunately they carry significant nephrotoxic effects 
inducing afferent arteriolar vasoconstriction leading to reduced 
glomerular filtration rate and arteriolar hyalinosis leading to 
obliterative vasculopathy and tubulointerstitial damage (Tantravahi 
et al., 2006). Azathioprine and mycophenolate mofetil (MMF) 
prevent T and B cell proliferation by inhibiting purine biosynthesis 
(Allison and Eugui, 2005). Sirolimus prevents cell cycle progression 
by blocking the ability of the T cells to proliferate in response to IL-2. 
T cell populations can be reduced by using antibodies against T cell 
antigens e.g. thymoglobulin, monoclonal antibody OKT3 and 
monoclonal antibodies against IL-2 receptors (CD25) which inhibits T 
cell expansion. These antibodies may be used for induction therapy 




Figure 1- 1 Acute rejection is thought to occur via T cell 
activation and current immunosuppressants target this 
pathway 
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1.1.3 Chronic allograft nephropathy (CAN) 
CAN is the final common pathway of permanent renal allograft 
injury. It has characteristic histological features, which result from 
the accumulation of various insults to the transplanted kidney. These 
histological features are distinct from those of acute rejection, overt 
drug toxicity and recurrent or de novo specific disease entities 
(Joosten et al., 2003). 
CAN is not synonymous with either chronic rejection which implies 
ongoing immunological activity or, chronic allograft dysfunction 
which suggests declining function, neither of which look at 
histological changes. (Nankivell and Chapman, 2006). 
Histological Findings 
The histopathological definition of CAN was developed from the Banff 
1997 working classification of renal allograft pathology. Four 
international meetings have been held in Banff Canada since 1991 in 
an attempt to standardise renal transplant pathology interpretation 
and reporting (Racusen et al., 1999). The diagnosis of CAN is made 
on one or more of the following histological findings: 
• Vascular changes  - ranging from sub endothelial inflammation 
to intimal hyperplasia and ultimately atherosclerosis. These 
arterial wall changes are accompanied by infiltration of the 
vessel wall by macrophages (Mφ) and foam cells (Elahi et al., 
2006).  
 8
• Glomerular Lesions  including mesangial proliferation, 
thickening and duplication of the basement membrane and 
glomerulosclerosis associated with ischaemia 
• Tubular atrophy - refers to the presence of tubules with thick 
redundant basement membranes, or a reduction of greater 
than 50% in tubular diameter compared to surrounding non-
atrophic tubules. 
• Interstitial Fibrosis - considered to be present when the 
supporting connective tissue in the renal parenchyma exceeds 
5% of the cortical area. 
(Joosten et al., 2003; Pascual et al., 2002; Yates and Nicholson, 2006).  
The hallmark of CAN is an accumulation of extracellular matrix 
(ECM), which may occur in the interstitium, intima of the blood 
vessels, or in the glomerulus causing the characteristic histological 
changes described above. (Joosten et al., 2003; Pascual et al., 
2002; Yates and Nicholson, 2006).  
The severity of CAN is graded using the 1997 Banff Schema which 
Takes into account the following histological lesions:  
• Interstitial fibrosis 
• Glomerulosclerosis 
• Mesangial matrix increase 
• Vascular fibrous intimal thickening 
• Arteriolar hyaline thickening 
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The lesions are then scored according to a severity scale 0-3; 
absence of any of the prespective lesions  severe pathology. 




Clinically the typical course of CAN is a gradual decline in renal 
function occurring at least 3 months after transplantation, but may 
be as late as many years following transplantation (Joosten et al., 
2005; Nankivell et al., 2003; Pascual et al., 2002). This loss of renal 
function is associated with falling creatinine clearance, a rise in 
serum creatinine and varying degrees of proteinuria and 
hypertension.  
The diagnosis is often made late in the disease process as the clinical 
signs lag behind the histopathological changes. 76% of patients have 
evidence of CAN in protocol biopsies before clinical deterioration 
becomes apparent (Viklicky et al., 2003; Yehia et al., 2006) 
 
Aetiological factors 
The mechanism of acute rejection is considered to be predominantly 
an immune process. CAN however does not seem to have one single 
aetiology but instead is multifactorial with a range of responsible risk 




• Acute rejection  late, multiple, and severe episodes are major 
risk factors. Acute vascular rejection carries a higher risk than 
cellular rejection.  
• Poor HLA match  
• Previous allosensitisation 
• Inadequate immunosuppression. 
Alloantigen independent /Non immune risk factors:   
• Donor age - There is a direct correlation between poor long-
term graft survival, the development of CAN and increasing 
age of the donor. This is attributed to the advanced age of the 
cells in general resulting in endothelial and epithelial atrophy 
and loss of function (Halloran et al., 1999; Yates and 
Nicholson, 2006). 
• Ischaemia/reperfusion (I/R) injury - Endothelial cell injury 
leads to up regulation of adhesion molecules and infiltration 
and activation of leucocytes resulting in increased alloimmunity 
of the graft. This creates a proinflammatory and profibrotic 
state within the graft (Joosten et al., 2003; Pascual et al., 
2002; Yates and Nicholson, 2006).  
• Delayed graft function secondary to ischaemia reperfusion 
injury and acute tubular necrosis. 
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• Brain death and donor morbidity  brain death up regulates 
certain immune cell derived cytokines which increases solid 
organ immunogenicity (Yates and Nicholson, 2006). 
• Calcineurin Inhibitors  have a deleterious effect on endothelial 
function. They also cause hypertension which is itself a risk 
factor for the development of CAN 
• Recipient morbidity  hypertension in the recipient is 
significantly associated with CAN and late graft failure 
(Halloran et al., 1999) 
The risk factors for the development of CAN occur at different time 
points throughout the life of the donor kidney (Nankivell and 
Chapman, 2006);  
Pretransplant - Quality of donor tissue and the technical aspects of 
organ procurement and transplantation e.g. quality of organ 
perfusion. 
Post transplantation  
• Early e.g. acute rejection, delayed graft function 
• Late e.g. subclinical inflammation/rejection (Moreso et al., 
2006), hypertension, calcineurin inhibitor nephrotoxicity, 
Cytomeglovirus (CMV) (Halloran et al., 1999). 
Nankivell et al put forward the theory that CAN consists of 2 distinct 
phases of injury: 
i. Early tubulointerstitial damage caused by I/R injury and 
immunological factors such as acute rejection. 
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ii. Later micro vascular and glomerular damage and progressive 
interstitial fibrosis resulting from calcineurin toxicity and 
subclinical inflammation (Nankivell et al., 2003; Nankivell and 
Chapman, 2006). 
 
1.1.4  Immunosuppressants and the treatment of CAN 
The prevention of acute rejection has improved since the 
introduction of the calcineurin inhibitors (CNI). Currently, no 
immunosuppressive regimen has been effective in the treatment or 
prevention of CAN (Elahi et al., 2006). The options for treatment of 
this condition remain very limited (ACE inhibitors for the treatment 
of blood pressure are considered in those patients with hypertension 
and proteinuria), and experimental, with no general consensus 
between centres.  
Calcineurin inhibitors (tacrolimus/cyclosporine) have been implicated 
as partly responsible for the fibrotic process seen in CAN (Afzali et 
al., 2005). Management of CAN has therefore concentrated on 
reducing exposure to CNIs by either reducing the dose delivered, 
with the risk of precipitating acute rejection or adding alternative 
immunosuppressants to enable either a reduction or complete 
withdrawal of CNI. Two options that are currently being investigated 
and used are a withdrawal of cyclosporine or tacrolimus and an 
introduction of either sirolimus or mycophenolate mofetil (MMF). 
 13
Sirolimus acts by binding to FK binding protein (FKBP). This complex 
then prevents progression of a cell from G1 to S phase of the cell 
cycle by inhibiting mTOR (mammalian target of Rapamycin). 
In this way it acts both as an immunosuppressant and anti- 
proliferative agent with the ability of inhibiting fibrogenesis (Afzali et 
al., 2005). Trials have reported a significant improvement in renal 
function and creatinine levels (>50%) when patients are switched 
from CSA or tacrolimus (Diekmann et al., 2001; Dominguez et al., 
2000). This may be due mainly to the withdrawal of CSA/tacrolimus 
rather than the introduction of sirolimus per se. The Leicester group 
carried out a trial of reducing CSA by 40% rather than complete 
withdrawal and failed to demonstrate any improvement in patients 
histological state or renal function (sirolimus can enhance CSA 
nephrotoxicity) (Saunders et al., 2003). It is also important to 
remember that sirolimus has significant side effects including 
hyperlipidaemia, thrombocytopenia, skin rashes and deranged liver 
function tests. 
MMF is a prodrug whose active metabolites inhibit the action of the 
enzyme inosine monophosphate dehydrogenase (IMPDH) required for 
the generation of purines in the S phase of the cell cycle. As with 
sirolimus it possesses both antiproliferative and immunosuppressant 
effects (Afzali et al., 2005).  
MMF has been associated with improved late graft function when given 
in place of CsA (Meier-Kriesche et al., 2003; Ojo et al., 2000). Dudley 
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demonstrated that with the cessation of CsA and substitution with 
MMF, renal function stabilised or improved in patients who had biopsy 
proven CAN (Dudley et al., 2005). Again this improvement may be 
due more to the cessation of CsA rather than the action of MMF. 
To date the trials into both these treatments are limited. In the main 
they have been conducted on a carefully selected group of patients 
and therefore are not truly representative of the true clinical setting. 
With sirolimus the studies have been small, mainly uncontrolled and 
with a short follow up. MMF studies are also small in number and 
again with short follow up, not extending beyond 2 years. With both 
these agents there is very little experience in patients with 
established CAN. 
So CAN remains a significant challenge with persistent rates of graft 
loss despite new and highly effective treatment against acute 











1.2  Macrophages 
1.2.1  Background 
Macrophages (Mφ) are present in low numbers within normal tissues 
throughout the body and act as sentinel cells. These differ 
phenotypically and functionally from infiltrating Monocyte-derived Mφ 
found in areas of local inflammation. 
At the inflamed site activated endothelial, epithelial and 
mesenchymal cells release chemokines and cytokines that signal 
naïve monocytes e.g MCP-1 (Monocyte chemoattractant protein -1). 
Once monocytes leave the circulation and enter the tissues they 
differentiate into Mφ. Naïve Mφ present at the inflamed site develop 
one of several phenotypic states dependent upon the nature of the 
microenviroment and activation stimuli. 
This heterogeneous population of Mφ are involved in the immune 
system. They contribute to the innate and acquired arms of the host 
immune response, the inflammatory response and tissue repair. 
They carry out a diverse number of roles including phagocytosis 
(Saville et al., 1989), antigen presentation and cytokine production 
with their response again being dictated by the mechanism of 
activation (Kluth et al., 2004; Wyburn et al., 2005). 
Several states of Mφ activation have been described including the 
following: 
Classical activation was the first mechanism to be described. This 
requires INFγ production by activated T cells and NK cells and the 
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presence of receptors able to recognise pathogen-associated 
molecular patterns e.g. TLRs (Kluth et al., 2004; Wyburn et al., 
2005). 
Classically activated Mφ defend against invading microbes, activate 
the adaptive immune response by presenting antigen to helper T 
cells via IL-12 production and they produce cytotoxic agents e.g. 
nitric oxide, TNFα. 
Alternative activation of Mφ. These Mφ are generated following 
exposure to IL-4 or IL-13 and do not release high levels of NO but 
increase expression of mannose receptor and MHC class Π. They 
therefore have very limited cytotoxic ability, and are more involved 
with tissue repair and fibrosis (Jakubzick et al., 2003; Stein and 
Keshav, 1992; Stein et al., 1992). 
Type II activation of Mφ. This activation state is induced by stimuli 
such as LPS or CD40L in the presence of IgG immune complexes. 
These Mφ are anti-inflammatory and release IL-10 but little IL-12 
(Mosser, 2003). 
Mφ phenotype following apoptotic cell ingestion 
Mφ  that phagocytose apoptotic cells also develop anti-inflammatory 
properties through their production of TGF-β, IL-10 and PGE2. 
Conversely a proinflammatory response can be induced through the 
ingestion of necrotic cells (Golpon et al., 2004).  
 17
1.2.2 Macrophage infiltration correlates closely to cell 
apoptosis in renal disease 
Mφ have been found to play an important role in renal injury (Kluth 
et al., 2004). Mφ infiltration correlates closely to vascular endothelial 
cell loss in various models of renal disease (remnant kidney model, 
unilateral ureteric obstruction, nephrotoxic tubular necrosis) (Kang 
et al., 2001a; Ohashi et al., 2000; Ohashi et al., 2002). In vitro 
studies indicate that cytokine activated Mφ induce mesangial cell and 
epithelial cell apoptosis (Duffield et al., 2000; Kipari et al., 2006; 
Kipari and Hughes, 2002). 
 
1.2.3 Macrophage infiltration associated with increased risk 
of acute and chronic allograft rejection 
Traditionally, as previously stated it has been the T cell that has 
been implicated in the immune response and rejection process in 
transplantation. There is however evidence to support the 
involvement of the Mφ in the process of organ rejection.  
Experimental models: 
In the rat cardiac allograft model apoptosis of the myocyte was 
paralleled by an increase in the number of Mφ present (Szabolcs et 
al., 1996). In the rat model of renal allograft rejection Jose showed 
that administration of the Mφ depleting agent clodronate ablated Mφ 




Human studies looking at renal allografts have mirrored the above 
findings. Croker et al studied biopsies from patients with delayed 
graft function or rising plasma creatinine after a period of stable 
renal function. They showed that the Mφ index (MI) provided a 
reliable indicator of graft survival with an increased MI correlating to 
reduced graft survival. (MI was taken to be the sum of Mφ scores in 
glomerulitis, tubulitis, interstitial nephritis and endovasculitis) 
(Croker et al., 1996). 
Mφ have also been considered a marker of rejection with graft 
outcomes proving significantly worse if intraglomerular Mφ are 
present (Ozdemir et al., 2002). In addition high Mφ numbers have 
been noted in first biopsy specimens of patients going on to develop 
chronic rejection compared to those who continue to enjoy stable 












Apoptosis occurs during development i.e. sculpturing tissues. In 
addition apoptosis can be detrimental e.g. tubular apoptosis in renal 
injury or beneficial e.g. PMN/ T cell apoptosis. 
Apoptosis is a form of programmed cell death, which occurs during 
tissue remodelling, tissue injury and the resolution of inflammation. 
Apoptosis removes unwanted cells that are surplus to requirements 
or those that are potentially harmful e.g. T cells.  (Hengartner, 
2000; Savill and Fadok, 2000; Weitzman, 2004). Apoptosis is 
characterised by condensation and fragmentation of nuclear 
chromatin, blebbing of intact membranes and cell shrinkage and 
fragmentation (Cailhier et al., 2006; Szabolcs et al., 1996). These 
morphological changes that characterise apoptosis are brought about 
by a set of cysteine proteases, which belong to a protein family 
known as Caspases. (Cailhier et al., 2006; Hengartner, 2000). 
Apoptotic cells are removed by the process of recognition and 
phagocytosis both by professional phagocytes i.e. Mφ and non- 
professional neighbouring cells i.e. epithelial cells and fibroblasts 
(Platt et al., 1998). Apoptotic cell recognition depends on expression 
of cell surface signals e.g. the phospholipid phosphatidylserine on 
the apoptotic cell (Savill and Fadok, 2000). This then triggers 
engulfment of the cell (Weitzman, 2004). This phagocytic clearance 
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is essential in the process of resolution of the inflammatory 
response.  
Phagocytosis of apoptotic cells prevents necrosis of the apoptotic 
cells which would lead to release of cytotoxic contents (Savill and 
Fadok, 2000; Weitzman, 2004) and suppresses the release of 
proinflammatroy mediators such as TNFα by the proinflammatory Mφ 
thereby modulating Mφ phenotype (Savill and Fadok, 2000).  
Apoptosis has previously been demonstrated in both normal 
developmental remodelling (Lang and Bishop, 1993) and various 
inflammatory states in the kidney (Duffield et al., 2000; Kipari et al., 
2006). In allograft rejection Szabolcs showed apoptosis of cardiac 
myocytes and endothelium during cardiac allograft rejection 
(Szabolcs et al., 1996).  
 
1.3.2 Mediators of Apoptosis 
1.3.2.1  Nitric Oxide 
Nitric oxide (NO) is generated from the conversion of L-arginine to L-
citrulline, a reaction catalyzed by the enzyme nitric oxide synthase 
(NOS). 
NOS isoforms: Three isoforms of NOS exist:  
• A neuronal form (nNOS), producing NO, which is a 
neuromodulator.  
• An endothelial form (eNOS) responsible for generating low 
levels of NO and maintaining low vascular tone.   
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• An inducible form (iNOS) first found and characterised in the 
Mφ. It is induced by a number of cytokines and inflammatory 
stimuli including IFNγ, TNFα, LPS, IL-1 and plays a role in the 
inflammatory response (Guzik et al., 2003; Kluth et al., 2004; 
Nitsch et al., 1997; Romagnani et al., 1999). Nitric oxide is 
known to be produced by the classically activated Mφ (Kluth et 
al., 2004). 
 
Role of NO in experimental models:  
In vitro iNOS generated NO has been shown to be a key death 
effector produced by the Mφ during the induction of both renal 
tubular cell and mesangial cell apoptosis as well as during 
tubulointerstitial inflammation in vivo (Duffield et al., 2000; Kipari et 
al., 2006). 
A substantial body of evidence points towards the involvement of NO 
in renal allograft rejection in various animal models, with high levels 
of interstitial iNOS expression in allograft but not isograft tissue. This 
expression has been localised particularly to infiltrating inflammatory 
cells and mononuclear cells. (Cattell et al., 1994; Worrall et al., 
1995). Further evidence for a detrimental role of Mφ produced NO 
comes from experiments showing a correlation between iNOS 
expression, Mφ infiltration and the extent of apoptosis in the rat 
model of cardiac allograft rejection (Szabolcs et al., 1996). Mφ 
depletion by clodronate and iNOS inhibition using aminoguanidine 
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attenuated the rejection process, though it should be noted that 
aminoguanidine is non-specific (Jose et al., 2003; Worrall et al., 
1995). 
 
The role of NO in human disease 
The involvement of NO in the human setting has also been explored. 
Kashem showed that there was no interstitial iNOS expression 
evident in normal kidney (Kashem et al., 1996). However in 
glomerulonephritis iNOS was present particularly in areas of high Mφ 
infiltration. In addition the renal biopsies of those patients with 
higher levels of iNOS expression exhibited greater renal damage and 
greater impairment of renal function (Kashem et al., 1996). In renal 
allograft rejection iNOS expression has been detected in the allograft 
and localised to infiltrating mononuclear cells (Romagnani et al., 
1999). Also, increased levels of nitrite were noted in the urine of 
patients with rejection (Smith et al., 1996). Additionally high levels 
of serum nitrate and nitrite have been noted in patients undergoing 
acute rejection (Albrecht et al., 2000; Romagnani et al., 1999; 
Smith et al., 1996).  
 
The role of NO in cell death or survival is concentration dependent. 
Physiologically low levels of NO inhibit T cell proliferation as well as 
cytokine and Fas-L induced apoptosis and is therefore 
cytoprotective.  At high concentrations NO is cytotoxic. iNOS has 
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recently been found to be constitutively expressed in human renal 
tubules and glomeruli and Du et al demonstrated that iNOS 
expression in  the donor kidney aids prolongation of graft survival in 
allogenic recipients (Du et al., 2006). Other studies as cited above 
suggest a destructive effect of iNOS generated NO on the allograft. 
Could this be explained by higher levels of NO being produced from 
Mφ iNOS under circumstances with large Mφ infiltrate? In addition 
this may be accompanied by a reduction in protective renal tubular 
cell derived NO due to destruction of the tubular epithelium. In this 
way the balance between protective and cytotoxic NO production 
may be tipped in favour of the cytotoxicity in the rejecting allograft. 
 
1.3.2.2  TNFα and Fas-ligand 
Fas-L and TNFα are pro-apoptotic factors. Both have bioactive 
membrane bound forms, which induce apoptosis by binding to 
homologous receptors - Fas (CD95) and TNFR 1 and 2 respectively. 
Fas and TNFR1 initiate caspase dependent death signalling by similar 
mechanisms (Akyurek et al., 1998) (Boyle et al., 2003). Various 
previous studies have investigated the role of FAS-L and TNFα in cell 
apoptosis and graft rejection. 
 
Animal models: 
Akyurek et al showed in the rat aortic transplant model that Fas-L 
was mainly expressed by T cells and Mφ. In this setting Fas mediated 
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apoptosis appeared to be involved in the lesions seen in chronic 
rejection (Akyurek et al., 1998). Soluble Fas blocks the binding of 
Fas to Fas-L and so acts as an apoptosis inhibitor. Wang et al 
blocked endothelial and smooth muscle cell apoptosis with over 
expression of soluble Fas and so reduced the development of 
transplant arteriosclerosis in the rat aortic transplant model (Wang 
et al., 2002). 
In vitro cell culture models 
a) Murine 
Gld/gld mice are homozygous for the point mutation in the Fas-L 
gene that results in a protein product unable to ligate Fas. Using 
bone marrow derived Mφ (BMDM) from these gld/gld mice Duffield et 
al (Duffield et al., 2000) showed that NO independent apoptosis of 
mesangial cells was not mediated by Mφ derived Fas-L.  Co-culture 
with mesangial cells primed with TNFα suggested a role for TNFα in 
the induction of Mφ mediated apoptosis in addition to NO. 
b) Human  
Using human Mφ Boyle et al showed that Mφ-derived TNFα 
contributed to Mφ−induced apoptosis of vascular smooth muscle cells 
(VSMCs). This was achieved both through up regulating iNOS 
expression and NO production by Mφ and increasing surface Fas-L 
expression. Blockade of the TNF receptors inhibited VSMC apoptosis 




1.4.1  Background. 
Lymphocytes are key cells of the adaptive immune system and 
impart specificity and memory to host defence as well as the 
capacity to discriminate between self and non-self from infectious 
pathogens providing self  non-self discrimination. After 
development from the myeloblastic stem cell those cells destined for 
the lymphocyte lineage undergo further maturation either in the 
thymus to form T cells or in the foetal liver and bone marrow to 
become B cells.  
 
1.4.2  T cells 
The maturation of T cells is characterised by a sequential appearance 
of certain cell surface molecules  CD3, T cell receptor (TcR), CD4 
and CD8 (fig 1-2). TcR recognises peptide antigen that is presented 
by MHC molecules. TcR also require the physical contact with CD3, 
which is necessary for transmembrane signalling leading to T cell 
activation. The TcR is also complexed with one of two molecules 
from the immunoglobin (Ig) superfamily (CD4 or CD8). 
CD4 helper T cells interact with MHC class Π found on specific 
antigen presenting cells  (B cells, Mφ and dendritic cells). They are 
principally regulatory cells, which control the function of other 
lymphocytes. Two separate subclasses of CD4 helper T lymphocytes 
exist based on their differing cytokine profiles - Th1 cells produce 
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cytokines such as IFNγ resulting in cell mediated immunity involving 
generation of both specific cytotoxic T cells and activated Mφ. Th2 
cells on the other hand make cytokines such as IL-4, IL-5 and IL-6, 
which are critical for the induction of humoral immunity and B cell 
activation (Graca et al., 2002; Kupfer and Singer, 1989; Martinez 
and Rosen, 2005). CD8 cytotoxic or suppressor T cells interact with 
MHC class 1 expressed on most nucleated cells. These cells 
participate in cell-mediated immunity against infections, certain 
tumours and play a role in immune regulation (Kupfer and Singer, 























1.4.3  B cells  
1.4.3.1  Antibodies and antigen presentation 
B cells act both as antigen presenting cells (APCs) as well as 
differentiating into antibody producing plasma cells. Mature B cells 
express MHC class Π molecules, CD20 and C3d. They can act as 
APCs by processing and presenting antigen complexed with MHC 
class Π molecules. This complex is then presented to the cell surface 
to CD4 helper T cells. Consequently T cells are activated to produce 
cytokines such as IL-2, IL-4, IL-10 that further stimulate 
proliferation and differentiation of the B cells. 
B cells intrinsically produce immunoglobins on their external 
membranes and once the mature B cell encounters the appropriate 
antigen the cell differentiates to form a plasma cell. These cells 
produce and secrete antibodies of one isotype with specificity for a 
single epitope. When antibodies bind to antigens they may neutralise 
pathogenic toxins, facilitate antigen ingestion by phagocytes 
(opsonisation), fix to and activate the complement system or 








1.4.3.2  The B cell and lymphangiogenesis 
The inflammatory process is known to be associated with leukocyte 
inflammation. Previously work has focused mainly on the 
monocyte/Mφ and T cells with little attention paid to the role of the B 
cell as an infiltrating cell. Recent studies looking at various models of 
renal disease including membranous nephropathy and renal allograft 
rejection have demonstrated the development of nodular infiltrates 
containing proliferating mature B cells expressing the chemokine 
receptor CXCR5 (Cohen et al., 2005; Heller et al., 2007; Kerjaschki 
et al., 2004). In addition, these nodular infiltrates were found to 
express the chemokine CXCL13 that is known to be associated with 
the accumulation of B cells expressing CXCR5 (Heller et al., 2007). 
This chemokine may therefore be important in the 
recruitment/accumulation of B cells within tissues. 
Importantly these nodular infiltrates have been found to be in close 
proximity to areas of neo lymphangiogenesis, suggesting that B cells 
may be crucial in the formation of new lymphatics (Heller et al., 
2007; Kerjaschki et al., 2004). This is in keeping with findings of 
previous studies, in which mice lacking CXCR5 are severely deficient 
in peripheral lymph nodes (Ansel et al., 2000).  
Using a mouse model immunised with complete Freunds adjuvant 
(CFA), which induces an immune reaction in lymph nodes, Angeli et 
al observed that lymphangiogenesis and lymph node (LN) expansion 
occurred resulting in increased dendritic cell (DC) migration to 
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draining lymph nodes. This process appeared to be dependent on B 
cells entering the LN and promoting lymphangiogenesis. B cell 
dependent enlargement of LNs and lymphangiogenesis, which 
facilitates the mobilization of DCs to LNs, would allow the priming of 
a T cell response of increased magnitude.  
Migration of APCs through lymphatics to draining lymph nodes 
represents a key step in the initiation of an adaptive immune 
response. Angeli et al provided evidence suggesting that the 
remodelling of the lymphatic network within the LNs enhances DC 
migration and that this process depends on the presence of B cells 
within the LN. In addition, VEGF-A expression was very prominently 
expressed by B cells within the lymph nodes supporting previous 
work indicating that VEGF-A may trigger lymphangiogenesis 
although the mechanism remains unclear (Hirakawa et al 2005: 
Nagy et al 2002: Ruddell at al 2003). 
In addition to the above findings Angeli et al also found that 
blockade of VEGFR-3 (the specific receptor for VEGF-C & D but not 
VEGF-A) also diminished immunization induced lymphangiogenesis 
(Angeli et al., 2006). This is consistent with findings by Cursiefen et 
al in the mouse model of inflammatory neovascularistion of the 
cornea. This indicated that VEGF-A stimulates haemangiogenesis 
through direct activation of VEGFR-2 on blood vessels as well as 
lymphangiogenesis via activation of VEGFR-1 on Mφ. These Mφ  
proceed to produce VEGF-C leading to activation of VEGFR-3 on the 
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lymphatic vessel. This then induces lymphangiogenesis through the 
production of VEGF-C acting via its receptor VEGFR-3 (Cursiefen et 
al., 2004). 
Selective blocking of VEGF-A using VEGF traps completely inhibited 
both haemangiogenesis and lymphangiogenesis and also reduced 
recruitment of inflammatory cells, specifically F4/80 positive Mφ. In 
addition depletion of Mφ either by γ irradiation or clodronate inhibited 
lymphangiogeneis (Cursiefen et al., 2004).  
Considering all the above findings we can surmise that the B cells 
produce VEGF-A, which activates the Mφ via VEGFR-1. Further 
speculation points towards these activated Mφ going on to produce 












1.5  The Endothelium 
1.5.1  Background  
Two distinct endothelial cell populations exist: vascular and 
lymphatic. These systems form non-anastamosing networks, which 
are functionally and structurally unique. Vascular endothelial lined 
blood vessels impart fluids, oxygen, nutrients, proteins and cells to 
the interstitium of the kidney whereas lymphatics serve as the exit 
route removing interstitial fluids and proteins. They also traffic APC 
to lymph nodes and are involved in tumour dissemination.  
 
1.5.2 Vascular endothelial growth factor family and their   
receptors. 
Vascular endothelial cell growth factor (VEGF) is a specific mitogen for 
endothelial cells. In mammals the VEGF family consists of 5 members; 
VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF). 
These members posses different physiological and biological 
properties and act through specific tyrosine kinase receptors; VEGFR-
1, VEGFR-2 and VEGFR-3. VEGF-A, B and PlGF bind to VEGFR-1, 
VEGF-A also binds to VEGFR-2 and VEGF-C and D bind to both VEGFR-
2 and VEGFR-3. This VEGF-VEGFR interaction is a key component in 
the process of angiogenesis and lymphangiogenesis (Olsson et al., 





Table 1- 1. Vascular endothelial growth factor receptors 
 
Receptor Expressed on Ligand 
VEGFR-1 Endothelial cells 
Pericytes 
Osteoblasts 
Monocytes and macrophages 









VEGFR-3 All endothelium during 
development. Lymphatic 





VEGF-A was the first member of the VEGF family to be identified 
(Senger et al., 1983). It is a heparin binding growth factor and acts 
through specific tyrosine kinase receptors VEGFR-1 and VEGFR-2 
(Roy et al., 2006). At least six different isoforms of  VEGF-A  are 
known to exist: VEGFA121, VEGFA145, VEGFA165, VEGFA183, VEGFA189 
and VEGFA206 (Roy et al., 2006). The most common isoforms are 
VEGFA121, VEGFA165 and VEGFA189 (Wakelin et al., 2004). VEGF-A is 
produced by a large variety of cells including Mφ, myocytes, 
neutrophils, fibroblasts and epithelial cells (Pilmore et al., 1999). 
VEGF-A production is up-regulated by hypoxia, cytokines, NO and 
various growth factors (Pilmore et al., 1999) (Wakelin et al., 2004). 
It acts as an endothelial cell mitogen and angiogenic factor, 
modulator of vascular permeability and serves as a chemoattractant 
for both monocytes and endothelial cells (Ozdemir et al., 2005). The 
function of VEGF-A in health is not fully understood but it has been 
suggested that it maintains endothelial cell integrity (Pilmore et al., 
1999). Several studies have found VEGF-A to be expressed in the 
normal human kidney, localising to the podocytes, distal tubular 
epithelium and collecting ducts (Ozdemir et al., 2005; Pilmore et al., 
1999; Simon et al., 1995). However in pathological states it appears 
to be responsible for angiogenesis associated with both hypoxia and 
tumour growth (Folkman, 1995). 
There are conflicting theories as to the production and action of 
VEGF-A during renal disease. The literature suggests that VEGF-A 
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expression by both infiltrating Mφ and local tissues initially increases 
in an attempt to repair and protect, resulting in early angiogenesis in 
the development of human allograft rejection (Ozdemir et al., 2005; 
Pilmore et al., 1999). However renal fibrosis eventually develops 
(Ozdemir et al., 2002; Pilmore et al., 1999). Supporting this theory 
two studies demonstrated up regulation of VEGF-A in CAN tissue 
(Ozdemir et al., 2002; Pilmore et al., 1999). There was increased 
expression in the tubular cells in addition to expression in the 
glomeruli, mesangial cells, interstitium and vasculature. In addition 
the interstitial Mφ appeared to be expressing VEGF-A. This is 
consistent with previous reports that VEGF-A expression is increased 
in chronic renal disease of various aetiologies and is associated with 
inflammatory Mφ infiltration (Simon et al., 1995). In the advanced 
stages of disease there is an overall reduction in VEGF- A production 
by the local tissues potentially due to inhibition by Mφ produced 
cytokines i.e. IL-1β, IL-6, TNFα (Kang et al., 2002; Masuda et al., 
2001; Ohashi et al., 2000; Ohashi et al., 2002). 
VEGF-B: Two isoforms of this growth factor are expressed in 
humans: VEGFB167 and VEGFB186. VEGFB167 accounts for over 80% 
of total VEGF-B and is expressed in most tissues including skeletal 
muscle, myocardium and brown fat. VEGFB186 is found at much 
lower levels and only in a limited number of tissues. VEGF-B binds to 
the receptor VEGFR-1. Its precise role in vivo is not precisely known 
although suggestions include involvement in the formation of 
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coronary collaterals and inflammatory angiogenesis (Roy et al., 
2006). 
VEGF-C is a lymphangiogenic growth factor that acts via VEGFR-3 or 
-2 (Cursiefen et al., 2002; Roy et al., 2006). It is often associated 
with inflammation, wound healing and tumour metastasis (Angeli et 
al., 2006). VEGF-C promotes proliferation and survival of cultured 
human Lymphatic Endothelial Cells (LECs) (Makinen et al., 2001; 
Podgrabinska et al., 2002). This is in contrast to VEGF-A which acts 
as a survival factor and promotes the proliferation of both blood and 
lymphatic endothelial cells through VEGFR-1 and -2 (Podgrabinska et 
al., 2002). In the murine model of suture induced corneal 
inflammation lymphangiogeneis is also apparent in these 
vascularised corneas. Here VEGF-C was found to be expressed both 
by the lining of corneal lymph vessels as well as by infiltrating 
inflammatory cells. This VEGF-C expression was up regulated by pro 
inflammatory cytokines (Cursiefen et al., 2002). In the rat remnant 
kidney model interstitial mononuclear cells were found to express 
VEGF-C (Matsui et al., 2003). In a subset of acutely rejecting human 
renal allografts with nodular mononuclear cell infiltrates Kerjaschki 
found that a subpopulation of Mφ within nodular infiltrates expressed 
VEGF-C (Kerjaschki et al., 2004).  
Skobe et al demonstrated that when VEGF-C overexpressing 
melanomas were transplanted into nude mice there was 
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development of intratumoral lymphatics and enlargement of existing 
lymphatics at the tumour periphery (Skobe et al., 2001). 
VEGF-D: This growth factor exhibits 48% homology to VEGF-C. It is 
expressed in many adult tissues including vascular endothelium, 
heart, skeletal muscle, lung and bowel (Roy et al., 2006). VEGF-D 
activates VEGFR-2 and VEGFR-3. VEGF-D is involved in endothelial 
cell proliferation and lymphangiogenesis (Roy et al., 2006). 
PlGF: Placental growth factor was first identified in the placenta but 
has since also been identified in the heart and lungs, PIGF enhances 
angiogenesis through VEGFR-1(Roy et al., 2006). 
 
1.5.3  Identification and phenotyping of lymphatic endothelial 
cells (LECs) vs vascular endothelial cells (VECs) 
Structurally the lymphatic capillaries are made up of a poorly 
developed basement membrane lacking pericytes. The lymphatic 
endothelial cells are connected directly to the interstitial collagen via 
anchoring filaments (Pepper and Skobe, 2003; Skobe et al., 2001). 
Until recently, unlike the vascular endothelium, little was known 
about the lymphatic endothelium. This was due to lack of 
histological, ultrastructural and immunohistochemical (IHC) markers 
to differentiate between LEC and VEC (Al-Rawi et al., 2005).  
Attempting to identify lymphatic vessels in routine histological 
sections relied on non-specific, suboptimal generalised features. 
This included absence of erythrocytes in the lumen, a wide lumen 
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with a thin partly overlapping endothelial lining, absent tight 
junctions and an absent or discontinuous basement membrane. 
(Cursiefen et al., 2003). 
Previously the only reliable modality to distinguish lymphatic from 
vascular structures was electron microscopy which showed the 
relative lack of basement membrane, fenestrations and cell junctions 
and their more prominent anchoring fibrils and vesicular transport 
system of LECs (Colvin, 2004). Although many endothelial cell 
markers exist and are used routinely in the identification and 
phenotyping of endothelial cells, they are non-specific and could not 
differentiate vascular from lymphatic endothelium. Recently specific 
(LEC) markers have become available and allow the separate 




Table 1- 2 Vascular and lymphatic endothelial cell markers 
 
Vascular endothelial cell 
marker 



















Hyaluronic Acid receptor protein 
 





















CD31 is a member of the immunoglobin super family and is a 
transmembrane glycoprotein. It is a constituent of the endothelial 
intercellular junction and plays a major role in the adhesion between 
the endothelial cell (EC) and recruited leukocyte during 
inflammation, and between ECs during angiogenesis. It is also 
present on the surface of platelets, monocytes, Mφ and neutrophils 
(Pusztaszeri et al., 2006).  
CD34 is a transmembrane glycoprotein and is present on ECs, 
leukaemic cells and stem cells. Although its function is still unclear, it 
is used in the diagnosis of leukaemia and the subclassification of 
vascular tumours (Pusztaszeri et al., 2006). It is used to purify 
progenitor cells. 
Von Willebrand Factor (vWF) is a glycoprotein that mediates 
platelet adhesion to matrix e.g. collagen at sites of vascular injury 
and binds and stabilises factor VIII in the circulation. It is expressed 
on ECs as well as in the cytoplasm of megakaryocytes. 
PAL-E is a monoclonal antibody that is specific for vascular 
endothelial cells of capillaries, medium sized and small veins and 
venules in frozen sections of human and some animal tissues. It 
does not stain the endothelial lining of lymphatic vessels. Using 
immunoelectronmicroscopy, the antigenic determinant recognized 
by PAL-E appears to be associated with endothelial 
vesicles.(Schlingemann et al., 1985). 
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Podoplanin: This is a glomerular podocyte mucoprotein involved in 
maintaining the glomerular barrier and the shape of the podocyte 
foot processes. It is also known to be expressed by lung alveolar 
type-1 cells, osteoblast and lymphatic endothelium (Al-Rawi et al., 
2005; Breiteneder-Geleff et al., 1999). Schacht et al found that the 
D240 antibody specifically recognises human but not mouse 
podoplanin (Schacht et al., 2005). 
This monoclonal antibody against sialoglycoprotein reacts with a 
fixation resistant epitope on the lymphatic endothelium found also 
on gonocytes of fetal testis (Arai et al., 2006; Fukunaga, 2005; Kahn 
et al., 2002). It has been found by several studies to be highly 
specific for lymphatic endothelium and unreactive to vascular 
endothelium (Arai et al., 2006; Galambos and Nodit, 2005; Kahn et 
al., 2002). As a result it has been used to separate mixed primary 
cultures of dermal endothelial cells into discrete vascular and 
lymphatic populations. (Kriehuber et al., 2001). 
LYVE-1: Lymphatic vessel endothelial receptor-1 is expressed on 
the cell surface as a 60kDa protein. It is a major receptor for 
hyaluronic acid on the lymph vessel wall. It is a type 1 integral 
membrane polypeptide with 41% homology to the CD44 hyaluronic 
receptor (Al-Rawi et al., 2005; Banerji et al., 1999).  
PROX-1: This transcription factor is a homologue of the Drosophilia 
homeobox gene prospero. During early development prox-1 
expression is induced on a sub population of endothelial cells 
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destined to become lymphatic endothelial cells. In the adult it is 
solely expressed by lymphatic endothelial cells (Al-Rawi et al., 2005; 
Cueni and Detmar, 2006). 
VEGFR-3: Vascular endothelial growth factor receptor-3 is also 
known as Flt4. It is a member of the fms-like tyrosine kinase family 
and specifically binds to VEGF-C and VEGF-D but not VEGF-A. It is 
therefore a lymphatic specific growth factor receptor and in normal 
adult tissues its expression is predominantly limited to the lymphatic 
endothelium (Cueni and Detmar, 2006). 
 
The introduction of these specific lymphatic endothelial cell markers 
has enabled the identification of distinct endothelial cell populations 
in tissues. (Kriehuber et al., 2001; Matsui et al., 2003). Also the 
isolation of these separate endothelial populations has become 
possible using antibodies to podoplanin (Kriehuber et al., 2001) 
Lyve-1 (Podgrabinska et al., 2002) and VEGFR-3 (Makinen et al., 
2001) coupled with flow cytometric cell sorting or immunomagnetic 









1.5.4  Vascular endothelial cell proliferation and rarefaction 
 There is increasing evidence that the microvasculature plays an 
important role in progressive renal disease (Kang et al., 2001b) 
(Ohashi et al., 2002). Loss of capillaries would lead to reduced 
delivery of oxygen and nutrients to the tubules and interstitial cells, 
resulting in hypoxia and ischaemia of the tissues and eventual tissue 
fibrosis (Kang et al., 2001a).  
The role of the vascular endothelium in the development of CAN is of 
particular interest as it forms the interface between donor and 
recipient cells and therefore is the first surface encountered by the 
recipients immune system (Cailhier et al., 2006). Injury to the 
endothelium occurs as an early event, leading to the development of 
a hypoxic state with chronic ischaemia. (Elahi et al., 2006; Viklicky 
et al., 2003). 
During renal disease it has been suggested that there may be an 
initial angiogenic response, possibly due to production of growth 
factors. Unfortunately this protective response is not sustained and 
is followed by progressive capillary loss (Ishii et al., 2005; Kang et 
al., 2001b; Ohashi et al., 2002).  This is possibly due to loss of an 
angiogenic factor e.g. VEGF-A, or increased expression of an anti-
angiogenic factor e.g. Thromospondin-1 (TSP-1) (Kang et al., 2001a; 
Kang et al., 2001b). 
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Several studies have reported increased vascular density in renal 
disease (Ozdemir et al., 2002; Pillebout et al., 2001). Possible 
explanations for this initial increase in vascularity are: 
1. Artifactual due to non specific endothelial cell markers which show 
a net increase in microvascularity due to an increase in lymphatic 
endothelial cells (Matsui et al., 2003). 
2. Initially in response to hypoxia, reparative Mφ are present from 
which Mφ derived VEGF-A is expressed or which stimulate increased 
VEGF-A production by the local tissues.  
 
This initial response is then followed by an increased number of pro-
inflammatory Mφ  which inhibit VEGF-A production by the local 
tissues (Kang et al., 2001a) or have a direct cytotoxic effect on the 
VEC. In addition there is gradual destruction of key resident renal 
cells e.g. podocytes, which produce VEGF-A. All the above factors 
lead to an overall reduction in microvascular density. 
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1.5.5  Lymphangiogenesis 
1.5.5.1  Background 
The importance of the lymphatic system as a pathway for tumour 
metastasis has been well recognised. Many cancers initially spread 
through the lymphatics with the extent of lymph node involvement 
being important in tumour staging and assessment of prognosis. In 
this context lymphangiogenesis has already been reported (Pepper 
et al., 2003; Skobe et al., 2001). The mechanisms underlying the 
process of lymphangiogenesis and its importance in other diseases 
remain unknown. 
  
1.5.5.2 Lymphangiogenesis and the Mφ 
Using various LEC markers, lymphangiogenesis has been found to 
occur in the peritumoral areas of several human tumours associated 
with tumour associated Mφ (TAM) infiltration (Schoppmann et al., 
2002). In addition lymphangiogenesis has been demonstrated in 
various inflammatory states (Pepper and Skobe, 2003; Skobe et al., 
2001) and is associated with Mφ infiltration and VEGF-C expression. 
Using the corneal suture model of inflammation, Cursiefen 
demonstrated increased lymphangiogenesis associated with VEGF-C 
expressing Mφ. Clodronate mediated local depletion of Mφ reduced 
corneal lymphangiogenesis (Cursiefen et al., 2002).  
Using LEC markers it has been demonstrated that in normal kidney 
tissue the lymphatic vessels follow the larger intrarenal branches of 
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the renal artery to the level of the interlobular arteries (Kerjaschki et 
al., 2004). No lymphatics are normally found in the interstitium. 
However in states of inflammation there is an increase in lymphatic 
vessel density with lymphatics now being found within the 
tubulointerstitial space (Kerjaschki et al., 2004; Matsui et al., 2003). 
In both situations this was accompanied by Mφ infiltration and VEGF-
C expression. 
 
1.5.5.3  Where do these new lymphatics come from?   
One possibility already suggested is that Mφ express VEGF-C which 
stimulates division of local pre-existent lymphatic endothelial cells 
acting through VEGFR-3 (Cursiefen et al., 2003; Kerjaschki et al., 
2006; Kerjaschki et al., 2004; Makinen et al., 2001). Other theories 
are that a progenitor cell exists; possibly VEGFR-3 positive 
monocytes which transdifferentiate into new lymphatics (Kerjaschki 
et al., 2006; Maruyama et al., 2005). Kerjaschki et al studies on 
human gender mismatched renal transplants using in situ 
hybridisation for the Y chromosome suggest that these progenitor 
cells are recipient derived (Kerjaschki et al., 2006). An additional 
theory is that vascular endothelial cells transdifferentiate into 
lymphatics under the control of IL-3 (Groger et al., 2004). 
 
 48
1.5.5.4  What is the role of these new lymphatic vessels?  
We do not know the exact nature of the lymphatic drainage of the 
transplanted kidney. Previous auto- transplantation work on limbs in 
rats show that lymphatic flow is restored but may follow a more 
superficial route (Mobley and O'Dell, 1967). In addition, the 
lymphatics may play an active role in leukocyte transport. The 
glycoprotein CLEVER-1 (common lymphatic endothelial and vascular 
endothelial Receptor-1), a member of the endothelial adhesion 
molecule family, is known to be expressed on lymphatic 
endothelium. CLEVER-1 mediates lymphocyte and peripheral blood 
mononuclear cell transmigration through the lymphatic endothelium 
and may play a role in the regulation of leukocyte egress from tissue 
(Salmi et al., 2004). 
The Chemokine receptor CCR7 must be expressed by T lymphocytes 
in order to exit peripheral sites and to emigrate to draining lymph 
nodes. The CCR7 ligand CCL21 is known to be expressed by 
lymphatic endothelial cells in extra lymphoid tissues (Debes et al., 
2005). 
This suggests that transmigration/efflux of lymphocytes from tissues 
into the lymphatic system is a highly regulated process possibly 
under the control of the lymphatic endothelium itself. Thus the 
lymphatic endothelium may play an active rather than a passive role 
in this process. 
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Are these new lymphatics good or bad? 
Lymphangiogenesis could feasibly be beneficial. New lymphatics may 
act to clear the inflammatory infiltrate from the kidney in an attempt 
to resolve the inflammatory process. Equally this extended lymphatic 
system could be harmful, with new lymphatics performing the 
following detrimental functions:  
1. Allowing continuation of the inflammatory process.  
2. Serving as pathways for the trafficking of antigen presenting cells 
thereby allowing these cells to migrate to lymph nodes and stimulate 
the adaptive immune response (Skobe et al., 2001). 
3. Active recruitment of inflammatory cells by the lymphatic 
endothelial thereby setting up tertiary lymphatic organs in which the 













1.6 Aims & Hypothesis 
I set out to explore the involvement of the macrophage on the 
vascular and lymphatic endothelium in the context of renal allograft 
rejection. 
 
The aim of this thesis was to investigate the following hypothesis: 
• Mφ induce vascular endothelial cell death by the production of 
pro-apoptotic death effectors such as NO, TNFα and FAS-L 
thereby contributing to microvascular rarefaction evident in 
transplanted organs. 
• Mφ support the production of new lymphatic vessels via the 















Chapter 2.  
     








2.1  Immunohistochemistry and immunofluoresence 
2.1.1  Tissue specimens 
Immunohistochemistry (IHC) and immmunofluoresence (IF) were 
performed on 3µm tissue sections fixed in either 10% buffered 
formalin or methyl carnoys solution (60% methanol, 30% 
chloroform and 10% acetic acid) and embedded in paraffin. Renal 
tissue from two species was studied: 
 
2.1.1.1  Human:  
Graft tissue available from 29 transplant nephrectomies diagnosed 
with CAN according to the Banff 1997 definition. Control tissue was 
obtained from the unaffected part of nephrectomy specimens from 
patients with a renal tumour (n=19) (see results section for patient 
details). 
 
2.1.1.2   Murine: 
2.1.1.2.1.  Model of murine renal transplantation 
Following administration of anaesthetic, donor kidney, ureter and 
bladder were harvested en bloc and transplanted onto recipient 
abdominal aorta, inferior vena cava and bladder. The right native 
kidney was removed at the time of transplantation whilst the left 
native kidney was left in situ. The experiment was terminated at day 
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7 when the histological picture was one of acute rejection (fig 2-1). 
All surgical procedures were performed by Dr Qi. 
Allograft:  Donor kidneys from wild type male Balb-c mice were 
transplanted into a recipient male FVB strain. This provided an H2 
mismatch and therefore at day 7 the histological picture was one of 
acute rejection (n=18). 
Isograft: As non-rejecting isograft controls, kidneys were 
transplanted between male FVB litter mates and culled at day 7 
(n=5) (fig 2-1). 
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2.1.1.2.2.  Conditional macrophage ablation in 
diphtheria toxin receptor transgenic mice. 
 
The expression of the human receptor for diphtheria toxin (DT) (also 
known as heparin binding epidermal growth factor (hbEGF)) in 
mouse cells confers sensitivity to DT in vivo. The human receptor is 
1000 fold more potent compared to the murine receptor such that 
injection of DT will kill murine cells that express the human DT 
receptor. Conditional Mφ ablation transgenic mice were generated 
using the construct CD11b-DTR. This used the CD11b promoter to 
provide Mφ specific expression (Cailhier et al., 2005). The Mφ and 
monocyte of this transgenic mouse (CD11b-DTR) specifically express 
the human diphtheria toxin receptor (DTR) such that monocyte/Mφ 
can be specifically ablated by the intraperitoneal injection of 
diphtheria toxin (Cailhier et al., 2005; Duffield et al., 2005). In this 
way conditional Mφ ablation is achieved following DT injection. 
 
Donors were male Balb/c to recipient transgenic cd11b male DTR 
(n=10). Treatment dose of DT 20ng/g was administered on day 3 
and 10ng/g on day 5 following transplantation. Our control allograft 
group was the transplantation of allograft donor male Balb/c to 
recipient FVB (n=18). DT was also given on day 3 and 5 to this 
control group in order to control for any non-specific effect of DT. 
The experiment was terminated at day 7 (fig 2-2). 
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Allograft: Donor  Balb/c male mice 
               Recipient  CD11b DTR male mice (n=10) 
               or non transgenic FVB/N male mice (n= 18) 
Isograft: Donor FVB/N male mice  
             Recipient FVB/N male mice (n=5) 
 
 
2.1.1.2.3.  Specimens obtained from the murine 
transplant recipient. 
 
Renal tissue, blood and urine samples were collected from the 
murine recipient to be used for experiments as outlined below. 
• Renal graft tissue was obtained at day 7 and used for IHC  
• Blood was taken from the recipient for flow cytometric analysis 
of circulating Mφ, T & B cells at day 7. 
• Urine was collected from the recipient via a bladder stab for 
analysis of nitrite and creatinine concentrations at day 0 pre 







Figure 2- 2 Murine transplants using CD11b-DTR mice 












2.1.2   Immunohistochemistry 
2.1.2.1  Method for Immunohistochemistry (IHC) 
Sections were dewaxed in xylene for 10 minutes and then 
rehydrated in descending concentrations of alcohol from 100% to 
65% for 2 minutes each. Sections were then washed in deionised 
water prior to the appropriate antigen retrieval technique. This was 
microwave heat treatment at 1000 watts in 500mls of deionised 
water with 5mls of Vector Antigen solution (Vector Labs, UK) unless 
otherwise stated. Endogenous hydrogen peroxide activity was 
blocked by incubating sections in 2% hydrogen peroxide (Sigma, 
UK) for 15mins on a rocking platform. Sections were then loaded 
into a sequenza in Shandon cover plates (thermoelectron 
corporation, UK) and washed with PBS (Oxoid BR). Avidin block 
(Vector, UK) was applied for 10 minutes followed by a PBS wash and 
Biotin block (Vector, UK) for 10 minutes. Following a further wash in 
PBS, protein block (DAKO Cytomation, Denmark) was applied for 10 
minutes before addition of the primary antibody diluted in antibody 
diluent (DAKO Cytomation, Denmark) (see table 2-1). After the 
appropriate incubation, the primary antibody was washed off and 
followed by application of the secondary antibody for 30 minutes at 
room temperature. Vector RTU peroxidase (Vector RTU Vectastain 
Kit, USA) was then applied for 30 minutes following a PBS wash. The 
substrate was then added  diaminobenzidine colour reagent (DAB) 
(DAKO Cytomation) for 5 minutes was used unless otherwise stated. 
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Counterstain was applied using haematoxylin and the slides were 
then cleared in increasing concentrations of alcohol (64% 100%) 
and then into xylene. The slides were finally mounted on cover slips 
with mounting medium. 
For methcarn sections the antigen retrieval step is omitted. Methcarn 
sections were used for all the murine IHC except CD31. As 
immunohistochemical controls, the primary antibodies were omitted 
and isotype controls specific to the primary antibody were also run. 
Positive control tissue for Lyve-1, VEGFR-3, CD20 and CD3 were 
human lung, placenta, Burkitts lymphoma and tonsil respectively. 
Formalin fixed sections required antigen retrieval carried out with 
5mls of vector antigen solution (Vector, UK) in 500mls of deionised 
water at high temperature for 15 minutes. 
Exceptions included: 
1) iNOS/LYVE-1/Ki-67: High temperature retrieval for 15 minutes 
in citrate buffer PH 6. 
2) CD3: Pressure cooker for 2 minutes in 1000mls antigen 
retrieval solution. 
3) CD31: Protease 12.5mg/100ml PBS preheated to 370C. 
Sections incubated for 20mins at 370C. 
• CD31  DAB was applied for 10mins and intensified in copper 
enhancement solution (6.66g cupric sulphate and 11.88g 
sodium chloride dissolved in 1000ml deionised water) applied 
for 5 minutes
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anti human CD68 
(DAKO, Denmark) 
1/400, 30mins RT 
Rabbit anti mouse 
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Rat anti mouse 
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Polyclonal rat anti 
Ki67  (abcam,UK) 
1/25 30mins RT 
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2.1.2.2  Double labelling :  
This technique was used in order to look for co-localisation between 
lymphatics and Mφ . The following flow diagram demonstrates IHC 
double labelling: 
                                  
                                         Dewaxing 
                                               ↓      
                                Antigen retrieval 
                                               ↓  
                       avidin     →    biotin    →   protein block 
                                              ↓ 
IHC #1  10 antibody  →  20 antibody  →  1st colour substrate (DAB) 
                                              ↓ 
                       avidin    →    biotin    →    protein block 
                                              ↓ 
IHC #2  10 antibody  →  20 antibody   →  2nd colour substrate      
                                                                 (VIP or Fuschin red) 
 
 







2.1.2.3  IHC analysis of tissue sections 
Human tissue 
1. Mφ Infiltration (CD68): Methods for quantifying CD68 
immunostaining in human tissue was discussed with Dr C Bellamy 
(renal pathologist) who recommended a semi quantitative scoring 
system graded 1-7 (zero-severe) as follows: 
        1= zero 
        2= minimal 
        3=mild 
        4 =mild-moderate 
        5=moderate 
        6=moderate-severe 
       7=severe 
A total of 20 fields (10 fields in the cortex and 10 fields in the 
medulla) were examined at x200 magnification and graded 1-7 for 
CD68 positive cell infiltration.  
2. Lymphatic Vessels (Podoplanin (D240) stain)  
20 fields at X200 magnification were analysed (10 fields in the 
interstitium and 10 fields in the perivascular region). The mean 
number of podoplanin or D240+ve vessels per field in the 
interstitium and perivascular region were determined (Kerjaschki et 
al., 2004). A lymphatic vessel was defined as a podoplanin positive 




1. Leukocyte infiltration (Mφ − F4/80, B cells  B220, T cells  CD3).  
For each section 10-15, fields including both cortex and medulla 
were examined and pictures were taken at x200 magnification. For 
quantification areas with positive staining for F4/80, B220 and CD3 
were measured using computer image analysis (website 
rsb.info.nih.gov/ij/). In each Image J field the positive areas were 
identified and expressed as a percentage of the total field area. 
(Kipari et al., 2006; Ohashi et al., 2002) (fig 2-4). 
 
2. Lymphatic Vessels (Podoplanin) 
Tissue sections were examined (x400 magnification) and the number 
of fully formed podoplanin positive lymphatics with a visible lumen 
per intra renal artery were counted.  
 
3. iNOS stain. Using a 25-point Chalkley graticle the number of iNOS 
positive interstitial cells and iNOS positive tubules were counted at 
x400 magnification. 10 cortical fields were examined. 
 
4. Peritubular capillaries (CD31) 
In each section 10-15 randomly selected fields including both cortex 
and medulla were examined and pictures were taken at x400 
magnification. Image J software was then used to count the number 
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of CD31 positive peritubular capillaries (PTC). For the exclusion of 
the effects of tubular dilation and atrophy on measured values, the 
number of tubules in each field was also counted and the number of 









         
        
 
Figure 2- 4 Image J analysis of F4/80 stain.  
Murine allograft tissue. In each field the positive areas were 
identified (example arrowed) and expressed as a percentage of the 






2.1.3 Immunofluorescence (IF) 
Immunofluoresence was used on the human sections to investigate 
co-localisation between two substances within the same cell, which 
would not be seen using IHC double staining. 
2.1.3.1  Method for IF 
The following flow chart describes the method for immunofuoresence 
staining: 
                                        dewax 
                                            ↓  
antigen retrieval →*  endogenous peroxide   →* protein block 
                                         block   
                                             ↓  
                     1st primary antibody diluted in PBS 
                                           *↓  
              1st fluorescent secondary antibody diluted in PBS 
                                           *↓  
                                     protein block 
                                             ↓  
                       2nd  primary antibody diluted in PBS 
                                           *↓  
            2nd  fluorescent secondary antibody diluted in PBS 
                                           *↓  
                                  aqueous mount 
* = washing steps 
Figure 2- 5 Method for immunofluorescent staining 
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*Each washing step was carried out in TBS x1, which is 100mls of x10 TBS 
diluted in 900mls of saline. X10 TBS was made up by dissolving 30.25g 
Tris Bas in 400ml-distilled water and adjusting PH to 7.6.  
A black box was used following addition of the fluorescent secondary  
to ensure that staining did not fade. 
The following controls were included: isotype control for primary 
antibody, secondary antibody alone with omission of primary 
antibody and no immunostaining (control for tissue autofluoresence). 
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2.1.3.2  Microscopes used for IF studies 
The microscopes used for analysis were the ZEISS LSM5 10 META 
and LEICA. Confocal laser scanning is a system based on an inverted 
motorised axiovert 200M stand with a LSM510 META scan head. It 





















2.2 Cell culture 
2.2.1  General reagents 
Tissue culture reagents were purchased from Life Technologies 
(Paisley, Scotland, UK). Tissue culture plastics were obtained from 
Costar (Loughborough, Leicestershire, UK) and Falcon (Runcorn, 
Cheshire, UK). Cytokines were purchased from R&D Systems 
(Abingdon, UK) and Peprotech EC Ltd (London, UK). 
L-N6- (1-iminoethyl)-lysine (L-NIL) and the control inactive isomer 
D-N6- (1-iminoethyl)-lysine (D-NIL) were purchased from 
Fluorochem Ltd (Old Glossop, Derbyshire, UK). All other reagents 
were from Sigma-Aldrich Company Ltd (Poole, Dorset, UK) unless 
otherwise stated. 
 
2.2.2   Murine cardiac endothelial cell (MCEC-1) 
2.2.2.1  Description 
MCEC-1 is a well established cell line isolated from transgenic mice 
harbouring the temperature sensitive simian virus 40 large Tag 
(tsA58 Tag) control gene under the H-2kb class 1 promoter. These 
cells proliferate at 330C and behave like primary cells at 370C 






2.2.2.2  MCEC-1 cell 
All work carried out in the tissue culture hood employed general 
sterile tissue culture techniques. The MCEC -1 cells were cultured on 
gelatin coated T75 flasks (1% gelatin) in full MCEC-1 media  
Dulbeccos Modified eagles Medium (DMEM) and 10% Fetal calf 
serum (FCS) (GIBCO BRL) with penicillin (100U/ml), streptomycin 
(100µg/ml), 2mM L-glutamine (GIBCO BRL) and endothelial cell 
growth factor (ECGF) (10U/ml) (Leo Laboratories Ltd, UK). These 
MCEC-1 cells were routinely cultured at 330C and maintained in 
culture by passaging cells when they were 70-80% confluent. The 
MCEC-1 cells adopted a cobble stone appearance when confluent. 
Intial stock cells were passage 1. Passages 5-9 were used in all the 
experiments, which were performed at 370C. 
 
2.2.2.3  Thawing and passaging cells 
A cryovial of frozen MCEC-1 cells that had been stored in liquid 
nitrogen (-1960C) was thawed by agitating the vial by hand in a 370C 
water bath. The contents were then transferred into a 15ml falcon 
tube containing prewarmed full MCEC-1 medium but no ECGF. This 
was spun for 5 minutes at 1000rpm (210g).  The medium was 
aspirated off and the pellet of cells resuspended in 10ml of medium 
plus ECGF. This was transferred to pre-prepared T75 flasks 
containing 5mls of warmed media. New T75 flasks were pre-coated 
with 1% gelatin and incubated at 370C for 30mins. This was then 
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removed by aspiration and replaced by 5mls of medium. When 
>70% confluent the cells were split 1:3 or 1:10 for slower growth 
according to when the cells were required for experiments. 
To release the endothelial cells the monolayer was washed twice in 
10mls of PBS without calcium or magnesium.  1ml of trypsin/EDTA 
was added and incubated for 2-3 min at 37oC.  The flask was firmly 
tapped to release cells and detachment was confirmed by 
examination under the microscope. The cells were resuspended in 
10ml of medium (no ECGF), transferred into 15ml falcon tube and 
centrifuged for 5mins at 1000rpm (210g). The medium was 
aspirated off leaving a pellet of MCEC-1 cells at the bottom. This 
pellet was resuspended in full MCEC medium with ECGF and added 
to the preprepared flask. 
  
2.2.2.4  Freezing and storage of cells 
The cells were detached as described above and resuspended in 
2mls of 10% dimethyl sulphoxide (DMSO) and FCS (90%). Two 1ml 





2.2.3  Culture of primary bone marrow derived macrophages 
(BMDM) 
2.2.3.1  Preparation BMDM 
BMDM were prepared from C57Bl/6 female mice as described 
previously (Duffield et al., 2000; Kipari et al., 2006; Kipari and 
Hughes, 2002). Briefly, bone marrow was isolated from the femurs 
by standard sterile techniques and matured for 7 days in 60ml non 
adherent teflon pots (R Vetter, Germany) in DMEM/F12 medium with 
10% FCS, penicillin (100U/ml), streptomycin (100ug/ml) and 20% 
L929 cell conditioned medium as a source of Mφ colony stimulating 
factor (M-CSF) to stimulate differentiation and maturation of 
Mφ. 10mls of the media was replenished every second day with fresh 
media. 
Characterisation of BMDM: Maturation and purity of BMDM at day 7 
were checked by performing a cytospin followed by Diff Quik 
staining. 100µl of cells in suspension were added to a cytospin holder 
containing a glass slide, piece of filter paper and a plastic well. The 
cells were then spun for 3 minutes at 300g. The cells attached to the 
glass slide and were then fixed with 100% methanol for 2mins, 
followed by staining in the Diff quik red solution for 1 minute and Diff 
quik Blue solution for 1 minute. All steps were performed at room 
temperature. The slides were rinsed with distilled water, left to air 
dry over night and finally cover slipped and mounted. Cytospins 
were examined under a microscope looking for Mφ morphology (fig 
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2-5). Phenotyping using flow cytometry has previously been carried 
out in our lab on these Mφ populations. 
 
Figure 2- 6 Characterisation of BMDM using cytospin and Diff 
Quick staining of BMDM in suspension at day 7 maturation 
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2.2.3.2  Macrophage supernatant harvesting 
250,000 Mφ in 24-well plates were cultured in 500µl of full 
DMEM/F12 medium for 24 hours in the presence or absence of IFNγ 
and LPS. After 24 hours, the supernatants were collected and 
centrifuged (40C , 5minutes, 4000g) to remove any cell debris. 
This supernatant was then used for: 
1. Co-culture with MCEC-1 cells. The Mφ supernatant was added 
to Tracker-green labelled MCEC-1 cells (50,000/well) and 
incubated for 24h at 370C.  
2. Griess Assay for analysis of nitrite concentration and specific 














2.2.4  Co-culture experiments 
The interaction between BMDM with MCEC-1 cells was studied using 
a co-culture assay well established in our laboratory (Duffield et al 
2000, Kipari et al 2006) (fig 2-7) 
    
 
   Target cell: Murine cardiac endothelial cells (MCEC-1) 
 
Figure 2- 7 In vitro co-culture assay of interaction between 




2.2.4.1  Direct co-culture between BMDM and MCEC-1 
MCEC-1 cells were prelabelled with fluorescent cell tracker green: 
MCEC-1 cells were washed in serum free MCEC-1 medium and 
incubated for 45 minutes with serum free medium containing CM-
green tracker dye at a concentration of 5ng/ml (Molecular Probes, 
Eugene, OR, USA). Cells were washed with medium containing 
serum to quench unbound tracker dye, then trypsinised and 1.5x104 
cells were added to 48 well plates to cover 70- 80% of the well 
surface area. Cells were allowed to adhere for 2-4 hours. Mφ were 
incubated for 30 minutes with fluorescent cell tracker orange at a 
concentration of 5ng/ml. Mφ were added to the MCEC-1 cells at a 
ratio of 2:1 Mφ:MCEC-1 cell as this ratio had been used previously 
(Kipari et al., 2006). Co-cultures were incubated for 3 hours before 
selected wells were activated with LPS (1ug/ml) and murine IFNγ 
(100U/ml). Non-activated wells were exposed to medium alone.  
The four experimental conditions were: 
• MCEC-1 cells alone (control well)  
• MCEC-1 cells activated with IFNγ/LPS  
• Co-culture non-activated in medium without cytokines  
• Co-culture activated with IFNγ/LPS.  
After 24 hours incubation the undisturbed wells underwent fixation 
with formaldehyde (4% final concentration) in order to ensure 
retention of apoptotic cells (Duffield et al., 2000; Kipari et al., 2006). 
Staining with Hoechst 33342 at 1ug/ml was then carried out for 15 
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minutes. Each experimental condition was carried out on three 
separate occasions. Mφ were derived from at least three different 
animals. 
 
2.2.4.2  Assessment of apoptotic cell retention in fixed co-
cultures 
Previous work indicated that formaldehyde fixation of the co-culture 
plates allowed fixation and retention of apoptotic mesangial and 
tubular cells. However apoptotic and necrotic cells do have the 
propensity to detach and float in the culture medium and therefore 
there was a risk of loosing these apoptotic cells before analysis. For 
this reason after 48 hours of fixation the formaldehyde solution 
containing any unattached cells termed floaters was collected in 
FACS tubes. This was washed with PBS and the washing fraction was 
also collected in the same tube. Centrifuge at 300g for 5minutes at 
40C was then carried out to remove formaldehyde and the 
supernatant was removed. The floaters resuspended in fresh PBS 
were then analysed using flow cytometry. 
Results showed that only a negligible proportion of the cells were 
lost, <1% of total cell number and so it was decided not to collect 




2.2.4.3  Assessment of MCEC-1 cell apoptosis and 
proliferation by fluorescent microscopy 
Analysis was carried out using inverted fluorescent microscopy. Five 
non-overlapping fields at high power (x400) were blindly chosen. 
Apoptotic MCEC-1 cells were identified by their green condensed 
cytoplasm and pyknotic nucleus. Mitotic MCEC-1 cells were 
recognised by their chromatin pattern and the presence of daughter 
cells. The total number of MCEC-1 cells were counted and expressed 
as a percentage of the control group (MCEC alone), which was 
depicted as 100%. 
 
2.2.4.4  Video microscopy 
Video microscopy was carried out using a NIKON microscope. 
(Eclipse TE2000-U). A co-culture experiment was set up as described 
above and activated co-cultures wells were analysed over an 18 hour 
time course with pictures being taken every 5 minutes. (see 
attached CD-ROM) 
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2.3   Griess Assay 
This reaction measures nitrite concentration in fluids. Nitrite is a 
stable and non volatile breakdown product of NO. The Griess assay 
was used to analyse murine Mφ supernatant and urine from murine 
transplant recipients. All reagents are from Promega Griess Reagent 
system unless otherwise stated. 
 
2.3.1  Method: 
50µl of Mφ supernatant was added to the wells of a 96 well plate in 
duplicate. Following addition of 50µl of sulphanilamide solution (1% 
sulphanilamide in 5% phosphoric acid) to all experimental samples 
and the wells containing the dilution series for the standard curve 
(Nitrite standard, 0.1M sodium nitrite in H2O), the plate was 
incubated at room temperature in the dark for 10 minutes. 50µl of 
0.1% N-1-Napthylethylenediamine dihydrochloride (NED solution) 
was added to all wells, and the plate was then incubated at room 
temperature in the dark for 10 minutes. Absorbance was measured 
in a plate reader with a filter between 520-550nm. 
A nitrite standard reference curve was produced by plotting the 
average absorbance value of each concentration of the nitrite 
standard against nitrite concentration. 
The average absorbance value of each experimental sample was 
calculated and its nitrite concentration was determined by 
comparison to the nitrite standard reference curve. 
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2.4   Enzyme linked immunosorbent assay (ELISA) 
ELISA was used to determine the TNFα concentration in murine 
Mφ  supernatant. 
2.4.1  Method  
ELISA was used to quantify murine TNFα from Mφ supernatants (N=3 
with Mφ from 3 different mice) according to the manufacturers 
instructions (R&D Systems, Abington, Oxfordshire, UK). Briefly, the 
goat anti-mouse TNFα capture antibody was diluted in PBS (1/180) 
and used to coat a 96 well plate (100µl/well). The plates were sealed 
and incubated overnight at room temperature. The capture antibody 
was removed and the wells were washed 3 times using ELISA wash 
buffer (PBS tablets) diluted in distilled water (1 tablet/100ml water) 
with 0.05% Tween-20, PH 7.2-7.4). 300µl of blocking buffer was 
applied to each well for 1 hour at room temperature (1% BSA in 
PBS, pH 7.2-7.4). Blocking buffer was aspirated and the wells 
washed 3 times with ELISA wash buffer. 
100µl of either standard in reagent diluent (1% BSA in PBS, pH 7.2-
7.4) or sample was applied to each well. Both standards and 
samples were run in duplicate. The plates were sealed and incubated 
at room temperature for 2 hours. 
Wells were washed 3 times with ELISA wash buffer and 100µl of the 
biotinylated goat anti-mouse TNFα detection antibody diluted in 
reagent diluent (1/180) was added to each well. Following a 2 hour 
incubation, the detection antibody was removed and the wells 
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washed with ELISA wash buffer. 100µl of strepavidin-HRP was 
applied to each well  (diluted in reagent diluent 1/200). The plate 
was covered and incubated for 20 minutes at room temperature. 
Further washing with ELISA wash buffer was followed by the addition 
of 100µl of substrate solution (1:1 mixture of colour reagent A 
(H2O2) and colour reagent B (Tetramethylbenzidine)) to each well 
and the plates were incubated for a further 20 minutes and 
protected from light. The reaction was then stopped by adding 50µl 
of stop solution (2N H2SO4) to each well. 
The optical density of each well was evaluated using a microplate 
reader (Dynatech Laboratories, USA) set to a wavelength of 450nm 




2.5  Flow Cytometric Analysis of Cells 
2.5.1  Fas Ligand expression by BMDM 
Mature BMDM were grown on 12 well plates (500,000/well) as 
previously described. After incubation at 370C overnight Mφ were 
detached from the tissue culture dish by scraping. Cells were blocked 
with 1% mouse serum and PBS for 15 minutes at 40C and incubated 
with FITC conjugated rat monoclonal antibody to Fas ligand (Abcam 
1: 100) or isotype control FITC conjugated Rat IgG2a (Bioscience, 
1:200) for 45 minutes at 40C in the dark. The positive control used 
was the cell line K5625 which is an erythroleukaemic cell line which 




2.6  Lymphatic endothelial cell identification & 
isolation 
2.6.1  Cells examined 
In an attempt to isolate a lymphatic endothelial cell population in 
vitro the following cells were studied:  
• Human umbilical vein endothelial primary cells (HUVCs) 
(Promocell, UK) 
• Human dermal microvascular primary endothelial cells 
(HUDMECs) (Promocell, UK) 
• Human dermal microvascular endothelial cell line (HUDMECs). 
(Gift from Centre for Disease Control and Prevention, Atlanta, 
Georgia) 
 
2.6.2  Method for passaging, freezing & thawing cells 
2.6.2.1  Passaging cells 
Cells were grown to 80% confluence in T25 flasks at 370C. 
Human dermal microvascular endothelial cell HDMEC (Cell Line):  
The medium was aspirated and the cell monolayer was washed twice 
with PBS without calcium or magnesium. 0.5mls of Trypsin/EDTA 
was added and the cells were allowed to detach at 370C for 3-5 
minutes with detachment checked by microscopy. 4.5mls of 
Clonetics endothelial basal medium (CAMBREX) with 10% FCS, 
1mg/ml hydrocortisone (Sigma, UK), 10ng/ml endothelial growth 
factor (BD), penicillin and streptomycin was added to the cells which 
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were then transferred into a 15ml falcon tube. Cells were counted 
using a haemocytometer and inoculated into new T25 flasks 
containing 5 mls of fresh full medium. 
Human dermal microvascular endothelial cells HDMEC (Primary 
Cells): The media was replaced with 5mls HepesBSS containing 
30mM Hepes, D-Glucose, sodium chloride, sodium phosphate, 
Phenol red (Promocell). This was then removed after 30 seconds and 
the monolayer was covered with 2.5mls trypsin/EDTA. When the 
cells were completely detached 2.5ml of trypsin neutralisation 
solution (Promocell) was added. The cells were then removed from 
the flask and centrifuged at 220g for 5 minutes. The clear 
supernatant was aspirated off and the pellet resuspended in 1ml of 
endothelial cell growth medium with FCS 2%, Endothelial growth 
factor 0.1ng/ml, hydrocortisone 1ug/ml, basic fibroblast growth 
factor 1ng/ml and endothelial cell growth stimulating hormone 
(ECGS/H) 0.4% (Promocell) before placing the seeded cells in a T25 









2.6.2.2  Freezing storage and thawing of cells 
The cells were detached as described above followed by 
centrifugation at 220g for 5 minutes at 200C. The medium was then 
aspirated off and the pellet resuspended in FBS and 10% DMSO for 
the cell line or Cryo-SFM (promocell) for the primary cells. 
The cells were thawed in a 370C water bath and then added to 10mls 
of full media in a 15ml falcon tube. This was centrifuged at 250g for 
5 minutes and the pellet was resuspended in 10mls of fresh medium, 
which was finally placed in a T25 flask and incubated at 37oC. 
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2.6.3  Methods for phenotyping cells 
 
2.6.3.1  Flow cytometry 
Method 
HDMECs cultured at 370C were grown to 80-90% confluence, 
detached from the T25 flask as previously described and transferred 
to a 15ml falcon tube. This suspension was then spun at 220g for 4-
5 minutes and the medium was aspirated off leaving the pellet of 
cells at the bottom. 
On ice: These cells were washed in PBS, centrifuged at 220g for 4 
minutes followed by a blocking step: 100ul of PBS -/- with 10% FCS 
per tube and left on ice for 10minutes. 
The primary antibody diluted in PBS and 10% FCS was then added 
and the cells were left on ice for 45 minutes. Cells were washed with 
FACS buffer (0.5% BSA in PBS) before incubation with the secondary 
antibody (diluted in PBS and 10% FCS) for 45 minutes.  
For double staining a further wash was performed after incubating 
with the secondary antibody before the second primary antibody was 
added. A final wash in ice cold PBS was then carried out before flow 
cytometric analysis of the cells. Controls consisted of: 
- Unstained cells. 
- Cells stained with the secondary antibody alone. 
- Cells stained with the isotype control antibody for the primary    





Cells were plated on cover slips (75,000 cells/cover slip) and placed 
in a 24 well plate in full medium overnight. Washing of the cells in 
PBS wth 0.1% BSA was then followed by fixation in ice-cold 
methanol: acetone 1:1 for 2 minutes. The cover slips were left to air 
dry for 20 minutes before the primary antibody (diluted in PBS with 
0.1% BSA) was added and incubated at room temperature for 1 
hour.  Three washes in X1 TBS preceded incubation of the cells with 
the secondary antibody (diluted in PBS with 0.1% BSA) conjugated 
to the fluorochrome for 30 minutes at room temperature. Further 
washing in x1 TBS followed by a wash in distilled H2O was carried 
out before mounting the slides in DAPI mounting medium. 
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2.6.3.3  Electron microscopy studies 
Approximately 100,000 cells  were plated on thermanox plastic cover 
slips in 24 well plates with 300µl of medium. When confluent the 
medium was aspirated off and the cells washed with PBS before 
being fixed with 3% glutaraldehyde in 0.1M sodium cacodylate buffer 
and placed in the fridge. 
Sections were then prepared by Steve Martin at the College of 
Vetinary Medicine, Edinburgh and transmission electron microscopy 

















2.6.4 Magnetic bead sorting of HDMEC cell line 
Method: 
HDMECs were grown to 80% confluence, detached from the T25 
flask and the cell pellet isolated as previously described. 
All steps were now carried out at 40C. The cell pellet was 
resuspended in 200µl of MACS buffer (200mls PBS with 1g BSA and 
800ul EDTA (Sigma, UK)), and incubated with 3µl of the human anti 
podoplanin antibody (Abcam, UK) for 20 minutes at 40C. The cells 
were then resuspended in MACs buffer and then incubated with 10µl 
of goat anti-mouse IgG microbeads (Miltenyi Biotec, UK) for 15 
minutes at 40C. Following a further wash, magnetic separation was 
carried out. The chilled separation column (Miltenyi Biotec, UK) was 
placed in the magnetic field of a MACS separator and prepared by 
rinsing with 3ml of buffer. The cell suspension was placed into the 
column and the unlabeled cells were collected in a 50ml falcon tube 
as they passed through - this was negative selection for podoplanin 
negative cells. The column was then removed from the separator 
and placed in a 15ml falcon tube and 5ml of buffer was pipetted into 
the column - these were the positively selected podoplanin positive  
cells. The cells were spun and resuspended in full medium. 2mls of 





2.7  Statistical analysis  
All results are presented as mean±SEM or median plus interquatile 
range. Statistical analysis was performed using GraphPad Prism 
3.02/Instat 1.1 (GraphPad software, San Diego, CA USA). The 
Students t-test was employed for comparisons involving two groups 
and statistical differences among multiple groups of data were 








Chapter 3.  
 
Analysis of the lymphatic 
and vascular endothelium 









3.1  Introduction 
In the studies outlined in this chapter immunohistochemical and 
immunofluorescent studies were undertaken on human renal tissue 
to investigate changes in the lymphatic system and infiltration of 
inflammatory cells occurring in the context of CAN. 
Previous work by my predecessor David Mitchell using CD31 
immunostaining of human renal tissue demonstrated a significant 
reduction in microvascular density in CAN tissue compared to control 
kidney tissue. In addition evaluation of endothelial cell cycle activity 
assessed with dual immunostaining with MIB-1 and CD31 
demonstrated significant endothelial cell proliferation in CAN tissue 
with very few MIB-1 positive endothelial cells in control kidney (Adair 
et al., 2007). Further studies went on to investigate the changes in 
lymphatic vessel density, inflammatory infiltrate and VEGF-A and -C 











3.2  Patient Information 
Regional ethical approval was obtained. Pathology reports from 
transplant nephrectomies performed at the Royal Infirmary of 
Edinburgh were reviewed by a pathologist looking for changes 
consistent with CAN.  
CAN tissue was available from 29 patients who underwent a 
transplant nephrectomy (age range 14-74, mean 40) and were 
diagnosed with CAN according to the Banff criteria (Racusen et al., 
1999). In our centre maintenance immunosuppression consists of 
triple therapy: calcineurin inhibitor, an antiproliferative agent e.g. 
azathioprine, and prednisolone. At allograft nephrectomy, the 
majority of patients (n=19) had stopped immunosuppressive 
therapy and all had restarted dialysis. The decision to remove the 
graft was made on clinical grounds such as recurrent infections, pain 
or to make a future transplantation procedure anatomically possible. 
Male patients comprised 61% of the CAN group and the mean time 
from transplantation to recommencing dialysis was 56.4 months 
(range 3.6 to 169 months). The mean time from recommencing 
dialysis to undergoing a graft nephrectomy was 6.4 months (range 
0.3 to 28 months) whilst 34.5% of patients had experienced a 
previous episode of acute rejection (table 3-1). Control tissue was 
obtained from macroscopically normal areas of nephrectomy 
specimens removed for renal carcinoma (n=19). The mean age of 
these patients was 53 years old at the time of nephrectomy   
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Table 3- 1 Details of patients with CAN whose renal tissue 
was studied in this work 
 
Number of patients 28 (29 discrete 
nephrectomies) 
Sex F:11 39% 
M:17 61% 












Congenital obstructive uropathy 







































Date of transplant 1986-2004 
Donor: Cadaveric 
            Living 
22 
7 
Donor age (years) 18-70  
mean 46.7 
Mismatch Full house 0 mismatch in 4 
14% 










time from transplantation to 
recommencing dialysis (months) 
3.6  169 
mean 56.4 
Time from recommencing dialysis 





3.3  Confirmation of endothelial staining in human 
tissue.  
Further immunostaining using CD34, an alternative specific 
endothelial cell marker was performed and this demonstrated a very 
similar staining pattern to CD31 (fig 3-1) 
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Figure 3- 1 Immunohistochemical staining of endothelial cells 
in human renal control tissue. 
Peritubular capillaries in human renal tissue were identified by 
immunohistochemical staining using the endothelial cell markers 
CD31 and CD34 
A Mouse anti human CD31 endothelial stain (example arrowed) 
(x200 magnification) 










3.4  Upregulation of interstitial lymphatics is seen 
within CAN tissue. 
In control kidney tissue the lymphatic vessels were located adjacent 
to arteries, as previously described with no lymphatic vessels evident 
in the interstitium (fig 3-2A). Immunostaining for lymphatic vessels 
was specific as they were identified with three different lymphatic 
markers: podoplanin (2 separate antibodies to podoplanin), LYVE-1 
and VEGFR-3 (fig 3-2 C&D). In the CAN tissue, 17 assessable cases 
showed podoplanin positive lymphatic vessels within the interstitium 
not associated with arteries but in close proximity to glomeruli and 
tubules (fig 3-2B) (some tissue sections did not show any podoplanin 
positivity and were therefore excluded). In addition, double 
immunostaining for CD68 and podoplanin demonstrated several 
interstitial lymphatic vessels containing CD68 positive cells thereby 
implying that they may function to facilitate the exit of inflammatory 
cells from the kidney (fig 3-3). 
Lymphatic vessels adjacent to large arteries or lying within the 
interstitium were quantified separately. Control and CAN tissue 
exhibited comparable numbers of lymphatic vessels situated in a 
perivascular location (fig 3-4). In contrast, interstitial lymphatic 
vessels were not identified in any control tissue section but 
significant numbers were evident within the diseased 
tubulointerstitium of grafts affected by CAN (fig 3-4). 
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Figure 3- 2 Staining of lymphatic endothelium in human renal 
tissue 
Lymphatic vessels in CAN and control tissue were identified by 
immunohistochemical staining for markers that discriminate vascular 
from lymphatic endothelial cells. 
A) Immunostaining for podoplanin using the antibody D240 in 
control kidney tissue: Podoplanin positive lymphatic vessels 
(arrowed) are evident lying in close proximity to a large intra renal 
artery. 
B) Immunostaining for podoplanin using the antibody D240 in CAN 
tissue; several podoplanin positive lymphatic vessels (arrowed) are 
evident within the tubulointerstitium adjacent to an atrophic 
glomerulus with periglomerular fibrosis. 
C) LYVE-1 immunostaining of a lymphatic vessel in control kidney 
tissue lying in close proximity to a large intra renal artery 
D) VEGFR-3 immunostaining of a lymphatic vessel in CAN kidney 











Figure 3- 3 Lymphatic vessel containing CD68 +ve Mφ in CAN 
tissue 
Immunostaining of human CAN tissue. Double labelling with the 
lymphatic endothelial cell marker podoplanin (purple) (arrowed), and 
the Mφ  marker CD68 (brown). Mφ are evident within the lumen of 

















Figure 3- 4 Lymphatic vessels are found in the interstitium of 
human renal tissue in CAN 
Lymphatic vessels in the perivascular and interstitial location were 
counted separately in tissue sections stained for podoplanin. In 
control kidney tissue, lymphatics were detected in the perivascular 
regions only. CAN tissue exhibited comparable numbers of 
perivascular lymphatic vessels but a marked increase in the number 
of lymphatic vessels was evident in the interstitium p<0.001*** 






3.5  Increased mononuclear cell infiltrate in CAN 
Phenotyping the mononuclear cell infiltrate in CAN tissue revealed a 
mixture of Mφ, T cells and B cells (fig 3-5). The B cell infiltrate was 
evident as both diffuse cell infiltration and as dense cellular 
aggregates. Control tissue exhibited negligible numbers of both B 
and T cells and as expected, low numbers of Mφ. Semiquantitative 
scoring revealed a significant increase in the number of infiltrating 
interstitial CD68 positive Mφ in both the cortex and the medulla in 





Figure 3- 5 Interstitial infiltrate of Mφ, T cells and B cells are 
present in the CAN tissue. 
Mononuclear cell infiltrate in CAN tissue was examined by 
immunostaining for leukocyte markers CD68 (Mφ), CD3 (T cells) and 
CD20 (B cells). 
Mφ infiltration in control tissue (A) and CAN tissue (B): Scattered 
CD68 positive Mφ are present in control tissue with increased 
numbers evident in CAN tissue. 
(C) Significant numbers of CD3 positive T cells are present within 
CAN tissue. 
(D) CD20 positive B cells are scattered throughout the interstitium 













Figure 3- 6 Increase in interstitial Mφ infiltrate is seen in the 
CAN tissue compared to control kidney tissue 
Semi quantitative scoring of CD68 positive Mφ infiltration indicated a 
significant increase in cortical and medullary infiltration of CAN tissue 








3.6  iNOS expression seen in CAN tissue co-localised 
to macrophage infiltrate. 
iNOS expression found in the interstitium of the CAN tissue was not 
visible in the interstitium of control tissue. In addition, dual 
immunofluorescent staining for CD68 and iNOS was performed and 
revealed a population of iNOS positive Mφ within the interstitium of 
CAN grafts (fig 3-7). 
 
3.7  Localisation of VEGF-A and -C expression 
VEGF-C expression found in the interstitium of the CAN tissue was 
not apparent in the control tissue (fig 3-8). Non quantitative 
assessment of VEGF-A immunostaining suggested that expression 
was localised to podocytes and tubular epithelial cells in control 
tissue with preserved expression in CAN (fig 3-9). Dual 
immunofluorescent staining for the leukocyte markers CD68, CD3 
and CD20 and VEGF-A and VEGF-C were performed. Occasional CD68 
positive VEGF-C expressing cells were present within the interstitium 
of CAN tissue but neither B cells nor T cells expressed VEGF-C (fig 3-
10). Interestingly, double labelling studies indicated striking co 
localisation of VEGF-A to interstitial B cell infiltrates whilst T cells and 






Figure 3- 7 Interstitial CD68 positive Mφ express iNOS 
Immunofluorescent staining of CAN tissue for the Mφ marker CD68 
(green) and iNOS (red). 
A CD68 positive Mφ are evident within the interstitium (example 
arrowed). 
B Expression of iNOS is evident in tubular epithelial cells as well as 
within the interstitium (example arrowed) 
C The merged image demonstrates co localisation of CD68 and iNOS 
indicating an iNOS positive Mφ (example arrowed)  
(x400 magnification). 
D A low power view of the merged CD68/iNOS image showing 
multiple CD68 positive cells expressing iNOS (example arrowed) 
(x200 magnification).  
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Figure 3- 8 VEGF-C immunostaining of human kidney tissue 
A VEGF-C expression present in the interstitium of the CAN tissue 
(arrowed) 




Figure 3- 9  Immunohistochemical staining of VEGF-A on 
human kidney tissue 
In control tissue VEGF-A expression is localised to the podocytes and 
tubular epithelial cells (arrowed) (A) with very low expression seen 
in the interstitium (B). In CAN tissue this podocyte and tubular 
epithelial expression is preserved (C) but significant interstitial 




Figure 3- 10 VEGF-C expression by the inflammatory infiltrate 
in CAN tissue. 
Dual immunofluorescent staining of CAN tissue was performed for 
the leukocyte markers CD68, CD3 and CD20 and VEGF-C. 
A Co-localisation of CD68 (green) and VEGF-C (red) demonstrates 
Mφ expression of VEGF-C 
B CD20 (green) and VEGF-C (red) do not co localise showing that B 
cells are not expression VEGF-C. 
C CD3 (green) and VEGF-C (red) do not co localise showing that T 










Figure 3- 11 VEGF-A expression by the inflammatory infiltrate 
in CAN tissue. 
Dual immunofluorescent staining of CAN tissue was performed for 
the leukocyte markers CD68, CD3 and CD20 and VEGF-A. 
A VEGF-A (green and CD68 (red) do not co localise showing that Mφ 
are not expressing VEGF-A 
B Striking co-localisation of CD20 (red) and VEGF-A (green) 
demonstrates aggregate B cell expression of VEGF-A 
C Striking co localisation of CD20 (red) and VEGF-A (green) 
demonstrates dispersed B cells also express VEGF-A 
D CD3 (red) and VEGF-A (green do not co localise showing that T 
cells are not expressing VEGF-A 
(x200 magnification) 
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3.8  Analysis of nephrectomy grafts with continued 
immunosuppression show comparable changes to 
results seen including all grafts 
In order to determine whether differences existed between those 
patients who had continued immunosupression compared to those 
whose immunosuppression had been withdrawn analyses between 
these two groups was carried out. In the patients whose 
immunosuppression has been stopped (n=19) the renal grafts may 
suffer acute rejection. In order to determine that the changes seen in 
the grafts are due to CAN and not acute rejection the sections from 
patients whose immunosuppession was continued at the time of 
nephrectomy were analysed separately (n=10). 
In this subset of tissue results were comparable to those reported 
from the group who had stopped immunosuppression except that 
there was a significant increase in cortical Mφ infiltrate in those 
continuing immunosuppression compared to those whose 
immunosuppression had been stopped (table 3-2). 
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Table 3- 2  Comparison between patients with 
immunosuppression continued or discontinued 
 












3.68±0.18 4.7±0.15  
(p<0.001 vs Gp A) 
1.86±0.23 
(p<0.001 
vs Gp A 





(p=NS vs Gp A) 
1.92±0.19 
(p<0.001 
vs Gp A 






(p=NS vs GpA) 
22.45±45 
(p<0.001 
vs Gp A 






(p=NS vs Gp A) 
21.48±0.56
(p<0.001 
vs Gp A 








(p=NS vs Gp A) 
1.31±0.39 
(p=NS vs 









(p=NS vs Gp A) 
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3.9  Summary & discussion 
In summary the studies outlined above demonstrate the following 
findings: 
1. CAN tissue exhibited an increase in number of lymphatic 
vessels within the interstitium. 
2. An increased interstitial Mφ infiltrate was evident in both the 
medulla and cortex of CAN tissue compared to the control 
group. 
3.  Interstitial infiltrate of both B and T cells was present in the 
CAN tissue but not present in the control group. The B cell 
infiltrate was both nodular and diffuse. 
4. Interstitial iNOS and VEGF-C expression is seen in the CAN 
tissue but not control tissue.  
5. VEGF-A expression is seen in the tubules of the control tissue. 
This is preserved in the allograft with the addition of interstitial 
VEGF-A expression. 
6. Some cells within the Mφ infiltrate appear to express both iNOS 
and VEGF-C but not VEGF-A. 
7. The B cells express VEGF-A but not VEGF-C and the T cells 






The human tissues used in these studies do have their limitations. 
The CAN tissues examined came from patients who are back on 
dialysis with the majority of patients off their immunosuppressants.  
However by analysing the patients whose immunosuppression had 
not been discontinued separately to those whose treatment had 
been withdrawn we found no difference between the groups (except 
an increase cortical CD68 Mφ in the immunosuppressed group) 
suggesting that our findings were related to CAN and were not 
simply due to stopping immunosuppression. 
These patients have ESRF and therefore we are seeing the process 
at a late stage. Ideally we would have also studied earlier biopsy 
tissue from these grafts as well as biopsy tissue from functioning 
grafts at a similar time post transplantation. This would have 
provided information about the progression of microvascular loss and 
lymphangiogenesis under normal circumstances. Unfortunately 
protocol biopsies are not carried out routinely at our centre and the 
tissue available from previous diagnostic biopsies was limited and 
not available for research purposes. 
 
The mean age of the patients from which the control renal tissue 
was taken was higher than that in the CAN group suggesting that 
age is not a confounding factor in this process and that the changes 
seen in  microvascular density are not age related but in fact are due 
to CAN.  
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The ideal control tissue would have been allograft tissue from a 
functioning graft with no evidence of acute or chronic rejection. 
 
Fixation of the tissues used in the studies was variable and some 
may have been left in formalin for several hours/days before being 
prepared. It is important to remember that CD31 is a pan 
endothelial cell marker and therefore does not distinguish between 
lymphatic and vascular endothelium. PAL-E is a specific VEC marker 
but is only effective on frozen sections, which was not available for 
these human tissue studies. We did however carry out a CD34 stain, 
which produced the same pattern of staining as our CD31 stain and 
confirmed that we were in fact staining endothelium rather than 
some other cell type. 
In figure 3-4 looking at podoplanin expression in the CAN vs. Control 
we see both an up regulation of lymphatics in the interstitium and a 
slight though not significant reduction in the perivascular number of 
lymphatic vessels. In the CAN tissue there is a loss of kidney tissue 
due to the disease, which could explain the apparent reduction of 
lymphatic number (but not significant) in the normal location. 
Analysis of proliferation in these lymphatics was not possible as 
multiple attempts at double staining using the proliferation marker 








Chapter 4.  
 
The role of nitric oxide in 






4.1  Introduction  
Previous studies have demonstrated that Mφ activated with LPS and 
INFγ induce direct apoptosis of both mesangial and primary tubular 
epithelial cells (Duffield et al., 2000; Kipari et al., 2006). In these 
systems NO appeared to act as the key death effector supporting 
earlier work showing a correlation between iNOS expression, Mφ 
infiltration and apoptosis (Szabolcs et al., 1996) .   
This thesis tested the hypothesis that activated Mφ induce direct 
endothelial cell death through the production of the death effector 
NO. In the studies outlined in this chapter a well established 
microscopically quantifiable in vitro co-culture assay was used. 
(Duffield et al., 2000; Kipari et al., 2006) to study the cytotoxic 
interaction between BMDM and MCEC-1 cells. This chapter describes 
the results of these studies that compared four experimental 
conditions.    
• MCEC-1 cells alone (control group) 
• MCEC-1 cells activated with the cytokines IFNγ and LPS 
• Non-activated co-cultures of MCEC-1 cells and BMDM 
• Co-cultures activated with IFNγ  and LPS 
Each experiment was repeated at least 3 times and each time the 
condition was carried out in triplicate. 5 fields in each well were 
examined and the number of apoptotic cells, mitotic cells and the 
total number MCEC-1 cells present were counted. Data was 
expressed as a mean ± SEM per high power field. 
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4.2  Co-cultures exhibit reduced endothelial cell 
mitosis that is independent of cytokine stimulation. 
Proliferation of endothelial cells was identified by the presence of 
mitotic cells seen by fluorescent microscopy (fig 4-1).  
The first observation was that mitosis was evident in control non-
activated MCEC-1 cell cultures and this was not affected by cytokine 
activation (fig 4-2 A). However this endothelial cell proliferation was 
completely inhibited when MCEC-1 cells were co-cultured with 
activated Mφ. In addition, proliferation was markedly inhibited when 
the MCEC-1 were co-cultured with non activated Mφ indicating that 
Mφ inhibition of endothelial cell proliferation is independent of 
cytokine activation (fig 4-2 A).  
Time course studies showed that at 6 hours in co-culture with 
activated Mφ endothelial cell proliferation was reduced by 76% with 
complete inhibition evident at 12hours (fig 4-2 B) 
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Figure 4- 1 Proliferating endothelial cells were evident in 
control co-culture wells. 
Cell tracker green labelled MCEC-1 cells were cultured with non-
activated Mφ  for 24hours at 370C. Following fixation with 
formaldehyde and counterstain with Hoechst 33342 analysis was 
carried out using fluorescent microscopy. Mitotic cells were identified 
by their characteristic chromatin pattern. 
A CM green labelled endothelial cell undergoing mitosis 
B Mitotic cells highlighted by Hoechst staining. 
(High power view x320 magnification) 
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Figure 4- 2 Inhibition of endothelial cell proliferation is Mφ 
dependant but cytokine independent. 
Cell tracker green labelled MCEC-1 were cultured alone or in the 
presence of cell tracker-orange labelled BMDM (Mφ:MCEC  2:1 ratio) 
with or without LPS (1µg/ml) and IFN-γ (100u/ml). After incubation 
at 370C co-cultures were fixed with formaldehyde, counterstained 
with Hoechst 33342 and analysed using fluorescent microscopy 
(n=3) 
A Expressing mitosis as the number of mitotic cells per high power 
field. After 24 hours incubation proliferation is completely abolished 
in activated co-cultures and markedly inhibited in non-activated co-
cultures. There was no significant difference in the level of 
proliferation between activated and non-activated groups. 
B Time course studies indicated inhibition of endothelial cell 




4.3 Cytokine activated co-cultures exhibit increased 
endothelial cell apoptosis 
Apoptotic endothelial cells were identified by their condensed 
cytoplasm and pyknotic nucleus seen using fluorescent microscopy. 
(fig 4-3). The number of apoptotic cells were counted and expressed 
as the number of apoptotic cells per high power field.  
The first thing observed was that no apoptosis was seen in 
endothelial cells cultured alone or in the presence of the activating 
cytokine IFN-γ and LPS proving that addition of cytokines alone was 
not cytotoxic to MCEC-1 cells. However the activated co-culture at 
24 hours exhibited a significant level of apoptosis that was 
significantly higher to that seen in non activated co-cultures at 24 
hours thus indicating that induction of MCEC-1 cell apoptosis was 
dependent upon cytokine activation of Mφ (fig 4-4 A). 
Kinetic analysis demonstrated that in the activated co-cultures there 
was no apoptosis apparent at 3 hours but increasing levels were 
seen from 6 hours (fig 4-4B). 
A low level of phagocytosis was seen in activated co-cultures at 12 
and 24 hours, but this was not quantified as it was an infrequent 





Figure 4- 3 Apoptotic endothelial cells in activated co-cultures 
Cell tracker-green labelled MCEC-1 cells were cultured in the 
presence of mature cell-tracker orange labelled BMDM. Selected co-
cultures were activated with LPS/INF-γ. Following incubation for 24 
hours at 370C the cells were fixed with formaldehyde and counter 
stained with Hoechst 33342. Using fluorescent microscopy apoptotic 
MCEC-1 cells were identified by their condensed cytoplasm and 
pyknotic nucleus. 
A CM green labelled apoptotic MCEC-1 cell (yellow arrow). CM green 
labelled healthy MCEC-1 cell (white arrow). 
B Hoechst stain demonstrating the pyknotic nucleus of the apoptotic 
cell (yellow arrow). Hoechst stain demonstrating the normal nucleus 
of the healthy MCEC-1 cell (white arrow) 
(High power view x320 magnification) 
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Figure 4- 4 Cytokine activated Mφ  induce MCEC-1 cell 
apoptosis. 
Cell tracker green labelled MCEC-1 were cultured alone or in the 
presence of cell tracker-orange labelled BMDM (Mφ:MCEC 2:1 ratio) 
with or without LPS (1mg/ml) and IFN-γ (100u/ml). After incubation 
at 370C co-cultures were fixed with formaldehyde counterstained 
with Hoechst 33342 and analysed using fluorescent microscopy 
(n=3). 
A Expressing apoptosis as the number of apoptotic cells per high 
power field. After 24 hours incubation cytokine activated Mφ  in co-
culture induce significant MCEC death compared to non activated 
Mφ  p<0.05* 
B A time course study was undertaken. MCEC-1 death appears to be 
induced by 6 hours in co-culture with activated Mφ. There is no 
significant difference in the level of apoptosis between 6 and 12 






Figure 4- 5 Occasional phagocytosis of endothelial cells was 
evident in activated co-cultures. 
Cell tracker green labelled MCEC-1 cells were cultured in the 
presence of mature cell-tracker orange labelled BMDM. Selected co-
cultures were activated with LPS/INF-γ.  Following incubation for 24 
hours at 370C the cells were fixed with formaldehyde and 
counterstained with Hoechst 33342. Using fluorescent microscopy 
occasional orange labelled Mφ could be seen ingesting green MCEC-1 








4.4 Cytokine activation of co-cultures results in a 
reduction of total number of MCEC-1 cells.  
Total endothelial cell number per hpf was determined and expressed 
as a percentage of the number of endothelial cells in control wells 
(depicted as 100%). 
The first finding was that culture of MCEC-1 cells with IFN-γ and LPS 
did not affect endothelial cell number indicating that IFN-γ and LPS 
are not inherently cytotoxic. Co-culture of MCEC-1 cells with non- 
activated BMDM for 24 hours did not induce a significant reduction in 
endothelial cell number. There was however a significant reduction in 
endothelial cell number in cytokine activated co-cultures compared 
to the control group (MCEC-1 cells alone) (fig 4-6A). 
The second observation was that there was a significant reduction in 
MCEC-1 cell numbers seen in the activated co-cultures compared to 
the non activated co-culture indicating that cytokine activation is key 
(fig 4-6A). 
Endothelial cell numbers were compared in the activated co-culture 
with the control group of MCEC-1 cells cultured alone at various time 
points. This indicated that a reduction in total MCEC-1 cell number in 
the activated co-cultures was only evident after 6 hours but this 




Figure 4- 6 Reduction in endothelial cell number is only seen 
in activated co-culture. 
Cell tracker green labelled MCEC-1 cells were cultured alone or in the 
presence of cell tracker-orange labelled BMDM (Mφ:MCEC 2:1ratio) 
with or without LPS (1µg/ml) and IFN-γ (100u/ml). After incubation 
at 370C co-cultures were fixed with formaldehyde and counterstained 
with Hoechst 33342. MCEC-1 cell number was expressed as the 
percentage of control cell number, which was designated as 100%. 
A There was a significant reduction in the MCEC-1 cell number 
expressed as a percentage of MCEC-1 cells in the activated co-
cultures compared to both the control group and the non activated 
co-cultures p<0.001*** 
B Kinetic analysis demonstrated MCEC-1 loss beginning at 6 hours 




4.5  Transferability of death signal 
In order to determine whether soluble mediators present in the 
supernatant from activated BMDM could induce apoptosis of MCEC-1 
cell experiments were performed involving transfer of supernatant 
from both non-activated and cytokine activated BMDM to MCEC-1 
cells. Conditioned supernatant from cytokine activated BMDM did not 
induce endothelial cell loss suggesting that the death effector 
responsible is either short lived or membrane bound (fig 4-7). 
Preliminary studies suggested that there was no effect on either 
proliferation or apoptosis. This was consistent with the findings of 
earlier work carried out by colleagues when studying the effect of 
supernatant from cytokine activated BMDM on tubular epithelial 
cells. No effect on proliferation or apoptosis was found in this 
setting. There was therefore no precedent to formally repeat these 





Figure 4- 7 The Mφ  death signal is not transferable. 
Conditioned supernatant derived from 250,000 mature BMDM/well 
and cultured for 24 hours in the presence or absence of LPS 
(1µg/ml) and IFN-γ  (100U/ml) was harvested and added to MCEC-1 
(50,000 cells/well). Following 24 hours incubation with the 
Mφ  supernatant, the wells were fixed with formaldehyde and 
endothelial cell number assessed using fluorescent microscopy. 
MCEC-1 cell numbers are comparable to the control groups (MCEC 
alone or activated with LPS and IFN-γ) whether incubated with 
activated or non-activated Mφ supernatant.  










4.6  Video microscopy 
Co-culture between IFN-γ and LPS activated Mφ and MCEC-1 cells 
was examined using video microscopy over an 18 hour time period 
with pictures being taken every 5 minutes as described in chapter 2. 
Using this method the interaction between the Mφ and MCEC-1 cell 
could be visually assessed. The Mφ appeared to be very dynamic 
moving freely within this system and the MCEC-1 cells could be seen 
lying both separately and in direct contact to the activated Mφ. Both 
the MCEC-1 cells in direct contact as well as those lying some 
distance from the Mφ were observed undergoing apoptosis with 
condensation of their cytoplasm and cell shrinkage. This 
demonstrated MCEC-1 apoptosis that was both dependent and 













4.7  Mediators of apoptosis 
4.7.1  Nitric oxide is implicated in this system 
Previous work in our group indicated the involvement of NO in both 
mesangial cell and tubular epithelial cell apoptosis  (Duffield et al., 
2000; Kipari et al., 2006). In the following experiments L-NIL a 
pharmacological inhibitor of iNOS was included in co-culture 
experiments with MCEC-1 cells to determine whether Mφ  derived NO 
was also involved in the induction of apoptosis of MCEC-1 cells. 
The generation of NO was determined by the Griess assay that 
measures nitrite, a stable breakdown product of NO. The Griess 
assay demonstrated that BMDM activated with LPS and IFNγ produce 
significant amounts of NO when compared to non-activated Mφ (fig 
4-8). 
Cytokine activated BMDM were then cultured in the presence of L-Nil 
or its inactive isomer D-Nil. The addition of L-Nil at a concentration 
as low as 10µmol was able to inhibit this nitrite production. Maximal 
inhibition was seen to occur with the addition of 30µM of L-Nil with 
no significant reduction seen with addition of an equal concentration 
of D-Nil (fig 4-8). A concentration of 30µM was chosen for both L-Nil 
and D-Nil in future experiments.  
Co-culture experiments were performed as previously described with 
the addition of L-Nil or D-Nil to the culture medium of the activated 
co-cultures. In the activated co-culture the number of apoptotic cells 
was 5±1.3 per hpf which was comparable to the level seen with the 
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addition of D-Nil (4.5±0.5 per hpf). The addition of L-Nil significantly 
reduced the level of MCEC-1 cell apoptosis to 0.24±0.14 per hpf (fig 
4-9). The inclusion of L-Nil inhibited MCEC-1 cell apoptosis by 
95±2.26% suggesting that NO is a key component of Mφ cytotoxicity 
in this assay. 
As predicted the addition of L-Nil to the activated co-culture 
preserved MCEC-1 cell number with no significant difference in cell 
number compared to the control group. There was however a 
significant difference in total number of endothelial cells present in 
activated co-cultures with or without L-Nil (18.2±1.7 vs. 10.2±1.8 
respectively; p<0.01). D-Nil had no protective effect on MCEC-1 cell 
number (fig 4-10) 
 135
 
Figure 4- 8 Nitrite produced by activated Mφ is effectively 
inhibited by L-Nil 
Conditioned supernatant was derived from 250,000 mature 
BMDM/well cultured for 24 hours in the presence or absence of LPS 
(1µg/ml) and IFN-γ (100U/ml) with or without L-Nil or D-Nil 
(concentration ranging from 10µm-50µm). Griess assay was carried 
out on this supernatant to assess the concentration of nitrite 
produced from Mφ under the above conditions. 
There was significantly increased nitrite production from Mφ 
activated with LPS and INF-γ compared to the non-activated Mφ 
p<0.05* 
Addition of L-Nil to the activated Mφ inhibited nitrite production 
maximally with 30µmol of L-Nil not seen with the addition of its 
inactive isomer D-Nil p<0.05* 
There was no significant difference in nitrite production between 
activated Mφ alone or the addition of D-Nil 
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Figure 4- 9 Apoptosis was almost completely abolished with 
the addition of L-Nil but not D-nil. 
Cell tracker green labelled MCEC-1 cells were cultured alone or in the 
presence of cell tracker-orange labelled BMDM. Cultures were 
activated with LPS (1µg/ml) and IFN-γ (100U/ml) in the presence or 
absence of the iNOS inhibitor L-Nil or its inactive isomer control D-Nil 
(final concentration 30µmol for both reagents). Cultures were 
incubated for 24 hours at 370C before fixation with formaldehyde 
and analysis using fluorescent microscopy. 
There was a significant reduction in the number of apoptotic cells 
seen with L- Nil addition compared to both the activated co-culture 







Figure 4- 10 Endothelial cell number is preserved by addition 
of L-Nil to activated co-cultures. 
Cell tracker green labelled MCEC-1 were cultured alone or in the 
presence of cell tracker-orange labelled BMDM. Cultures were 
activated with LPS (1µg/ml) and INF-γ (100U/ml) in the presence of 
absence of the iNOS inhibitor L-Nil or its inactive isomer control D-Nil 
(final concentration 30µmol for both reagents). Cultures were 
incubated for 24 hours at 370C before fixation with formaldehyde 
and analysis using fluorescent microscopy.  
With the addition of 30µmol L-Nil there was no significant difference 
in endothelial cell number compared to the control group. There is a 
significant difference in endothelial cell number in the L-Nil group 
compared to either the activated co-culture or D-Nil groups 






4.7.2  TNFα production by activated macrophages is not 
inhibited by the addition of L-Nil 
TNFα may also be an important death effector in this system. Thus a 
TNFα ELISA was performed to establish whether INF-γ and LPS 
activated Mφ produce significant levels of TNFα and whether TNFα 
production was affected by the addition of L-Nil. Significant 
TNFα production by activated Mφ was evident compared to non-
activated Mφ (2542±22 vs. 3.24±89pg/ml; p<0.001). TNFα 
production was not inhibited by the addition of L-NIL or D-NIL (fig 4-
11).  
This suggests that TNFα does not play a major role in the induction 
of endothelial cell apoptosis in this co-culture assay system since 
apoptosis is inhibited with the addition of L-Nil despite continued 
TNFα production. In addition the profound reduction in MCEC-1 
apoptosis (>90%) by the addition of L-NIL suggests that NO is the 
dominant death effector in this system. 
 
4.7.3  Fas-L is not expressed by the activated BMDM 
Using flow cytometric analysis our positive control cell KFL9 (derived 
from the parent cell K5625 a leukaemic lineage transfected with Fas-
L) can be seen to express modest amounts of Fas-L. Analysis of 
BMDM indicates that FAS-L is not expressed to a significant level 





Figure 4- 11 L-Nil does not effect TNFα production by 
activated Mφ 
Using an ELISA kit the supernatant from Mφ incubated for 24 hours 
with and without LPS/IFN-γ and with the addition of either L-Nil or D-
Nil were tested for TNFα production. Activated Mφ produce 
significantly higher levels of TNFα than non activated Mφ 
p<0.0001***. This TNFα production is not inhibited with the addition 







Figure 4- 12 FAS Ligand is not expressed by bone marrow 
derived Mφ 
Mature BMDM were cultured for 24 hours on a 12 well plate 
(500,000 cells/well) activated with LPS/IFNγ. They were then 
scraped of the culture plate and stained with Rat anti-mouse Fas-L 
antibody or an isotype control Rat IgG2 followed by FITC conjugated 
secondary antibody prior to flow cytometric analysis. Control group 
of activated Mφ with no FAS-L antibody was also analysed. 
A Flow cytometry analysis demonstrates no difference in the FAS-L 
stained Μφ compared to either the unstained group or the isotype 
control suggesting that there is no FAS-L expression by these 
activated Mφ. 
B The positive control KFL9 cell line demonstrates a shift to the right 
on the histogram compared to the control group demonstrating Fas-
L expression 
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4.8 Summary & discussion 
The in vitro studies aimed to dissect the mechanism of endothelial 
cell death by cytokine activated Mφ. Previous work in our lab has 
shown using in vitro co-culture techniques that activated Mφ are 
cytotoxic to both mesangial cells and tubular epithelial cells. In these 
studies the data demonstrates that activated Mφ are directly 
cytotoxic to endothelial cells in vitro both by inducing apoptosis as 
well as inhibiting proliferation. However, the inhibition of 
proliferation was independent of cytokine activation. 
Mφ activation was achieved with the use of LPS and IFNγ. This 
method of activation was chosen in an attempt to mirror classical 
activation of the Mφ, which would occur through IFNγ production, by 
the T cell. In this way I attempted to mirror an immune response  
in vivo where the T cells would activate Mφ via IFNγ.  
The endothelial cells used in this experiment were from CBA/CA x 
C57/BL10 strains. The Mφ we used were from murine C57 BL/6 
females.  
It has been found from previous work in our group that different 
strain combinations did not affect the level of apoptosis of tubular 
cells in co-culture. In addition it is very unlikely that there is an 
allogeneic reaction occurring in the co-culture as no immune 
reactants i.e. T cells, antibodies are present. For these reasons we 
did not attempt alternative strain combinations in this work. 
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We used a cardiac microvascular endothelial cell as opposed to a 
renal endothelial cell because at the time of these experiments this 
was the only microvascular cell line available. Since completing 
these experiments a paper was published by Rops et al (Kid 
International Dec 2004), which used a glomerular endothelial cell 
line. I contacted the author of these studies but had no response and 
this cell line was not commercially available. 
After first determining that our Mφ do indeed produce NO when 
activated we successfully blocked this production using L-Nil, with 
the inactive isomer D-Nil as control. This appeared to exert a 
significant protective effect on the endothelial cell preventing both 
apoptosis and the resultant endothelial cell loss, in contrast the 
addition of D-Nil was not protective. 
The possible involvement of additional death effectors in our system 
including TNFα and Fas-L was explored. Significant levels of TNFα 
were produced by activated Mφ, with TNFα levels being unaffected by 
the addition of L-Nil. Since L-NIL produced such a profound inhibition 
of endothelial cell apoptosis in the presence of continued expression 
of TNFα it is likely that TNFα is not a key player in this co-culture 
system. 
Fas-Ligand, another potential death effector did not appear to be 
expressed by our activated Mφ.  
This evidence suggested that the major death effector in our in vitro 
system was NO. 
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In the human setting, TNFα and FAS-L may have more involvement 










Chapter 5.  
 
The vascular & lymphatic 
endothelium in 




5.1  Introduction 
The murine model of acute renal allograft rejection was developed 
by my supervisor Miss Lorna Marson. The strain combination used 
for the allograft was donor Balb-c to FVB recipient. This provided an 
H2 haplotype mismatch such that termination of the experiment at 
day 7 produced the histological picture of acute rejection as 
confirmed by our renal pathologist Dr Bellamy. The Isograft control 
was donor FVB to recipient FVB. 
Results from in vitro experiments described in the previous chapter 
indicated a key role of the Mφ in endothelial cell apoptosis. We used 
a conditional Mφ ablation model (Cailhier et al., 2005) to investigate 
the effect of Mφ depletion upon the renal microvascular endothelium 
in the murine model of acute renal allograft rejection. Here the 
donor was Balb/c to recipient FVB-CD11bDTR. A single surgeon Dr F 










5.2  Macrophage infiltration seen in allografts was 
reduced by diphtheria toxin injection 
Very low numbers of F4/80 positive cells were seen in the isograft 
tissue. In contrast the allografts exhibited marked infiltration with 
interstitial F4/80 positive cells. Mφ infiltration of the allograft was 
significantly reduced following DT treatment (fig 5-1). Computer 
image analysis was used to quantify the extent of F4/80 positive Mφ 
infiltration with data being expressed as the percentage of F4/80 
staining per total slide area. Interstitial Mφ infiltration significantly 
increased in the medulla of the allograft compared to the isograft 
(0.77±0.39 vs 5.77±1.04 % area isograft vs allograft; p=0.0034). An 
increased infiltrate of F4/80 positive cells was also evident in the 
cortex although this did not reach statistical significance (fig 5.2). 
With the administration of DT the F4/80 positive Mφ infiltrate in both 
the cortex and medulla were significantly reduced compared to the 
allograft controls. Cortex (1.01±0.46 vs 3.78±0.78 % area, Mφ 
ablation injection v control allograft; p<0.05). Medulla (0.77±0.39 vs 
2.36±0.68 % area, Mφ ablation vs control allograft; p<0.05) (fig 5-2) 
There was no significant difference in Mφ infiltration between the 
isograft and the Mφ ablated allograft.  
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Figure 5- 1 Murine allografts exhibit increased Mφ infiltration 
which is reduced following DT treatment. 
F4/80 immunostaining performed in murine transplanted renal tissue 
harvested as day 7. Isograft FVB→FVB (n=5). Allograft Balbc→FVB 
(n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
A Isografts exhibited little interstitial Mφ infiltration. B Allografts 








Figure 5- 2 Mφ ablation is achieved by injection of diphtheria 
toxin. 
F4/80 immunostaining was performed on murine transplanted renal 
tissue harvested at day 7 and quantified by computer image 
analysis. Isograft FVB→FVB (n=5). Allograft Balbc→FVB (n=18). Mφ 
depleted Balbc→CD11b-DTR (n=10). 
There is significant medullary infiltration of F4/80 positive Mφ in 
allografts compared to the isografts p<0.001***. This Mφ infiltration 
is significantly inhibited both in the medulla and cortex of allografts 






5.3  T and B cell infiltration was not affected by DT 
injection 
Very little T cell infiltration was seen in the isografts. In contrast a 
large interstitial T cell infiltrate was evident in both the control 
allograft the Mφ depleted tissue (fig 5-3). Quantifying these 
observations and expressing our findings as the percentage CD3 
staining per field area we found almost negligible numbers of T cells 
in the interstitium of both the cortex (0.25±0.07) and medulla 
(0.15±0.04) of the isografts (fig 5-4) 
Significant T cell infiltration was found in the allograft cortex and 
medulla compared to the isografts, (8.74±0.76 vs 0.25±0.07 % area; 
Mφ depleted cortex vs control isograft cortex; p<0.001) (6.8±0.86 vs 
0.15±0.04 % area Mφ depleted medulla vs control isograft medulla; 
p<0.001).  
The Mφ depleted allografts also exhibited significantly higher T cell 
infiltration compared to the isograft; Cortex (7.58±1.50 vs 25±0.07 
% area, Mφ depleted vs control isograft; p<0.001), medulla (4.7±1.4 
vs 0.15±0.04 % area; Mφ depleted vs control isograft; p<0.001). 
There was no significant difference in T cell infiltrate between control 




Figure 5- 3 Allografts exhibit increased interstitial T cell 
infiltration, which is not reduced by DT treatment. 
CD3 immunostaining was performed on murine transplanted renal 
tissue harvested at day 7. Isograft FVB→FVB (n=5). Allograft 
Balbc→FVB (n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
A Isograft exhibits little interstitial T cell infiltration. B Allografts 
show a large T cell infiltrate. C Significant T cell infiltrate is still 









Figure 5- 4 Diphtheria toxin mediated monocyte Mφ ablation 
does not affect T cell infiltration in murine renal allograft 
tissue. 
CD3 immunostaining performed on murine transplanted renal tissue 
harvested at day 7. Isograft FVB→FVB (n=5). Allograft Balbc→FVB 
(n=18). Mφ depleted Balbc→DTR (n=10). 
There is significant infiltration of T cells in control and Mφ ablated 
allografts compared to the isografts p<0.001***. This T cell 









Very little B cell B220 +ve infiltrate was seen in the isografts. In 
contrast a large interstitial B cell infiltrate comprising of both B cell 
aggregates and dispersed B cells was evident in the control allograft 
the Mφ depleted allograft (fig 5-5). B cell infiltration was quantified 
by computer image analysis and the data expressed as the 
percentage of B220 positive immunostaining per field. Almost 
negligible B cell infiltrate in the isografts was found; cortex 
(0.009±0.005 % area) medulla (0.016±0.01 % area). There was a 
significant infiltrate seen in the allografts compared to the isograft; 
cortex (0.68±0.15 vs 0.009±0.005 % area allograft vs isograft; 
p<0.001), medulla (0.15±0.03 vs 0.016±0.01 % area allograft vs 
isograft; p<0.05).  
B cell infiltration in control allograft and Mφ depleted allograft were 
comparable (Fig 5-6) 
The level of circulating mononuclear cells was determined at the end 
of the experiment on day 7. There was a significant reduction in 
circulating monocytes in the Mφ depleted group compared to the 
control allografts. There was also a significant reduction in circulating 
B cells compared to the allografts. There was no difference in 
circulating CD4 or CD8 T cells between Mφ depleted and control 




Figure 5- 5 Allografts exhibit increased interstitial B cell 
infiltration, which is not inhibited by DT treatment. 
B220 immunostaining performed on murine transplanted renal tissue 
harvested at day 7. Isograft FVB→FVB (n=5). Allograft Balbc→FVB 
(n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
A Isograft exhibits little interstitial B cell infiltration. B Allograft 
shows a large B cell infiltrate. C Significant B cell infiltrate is still 










Figure 5- 6 Diphtheria toxin mediated monocyte/Mφ ablation 
does not affect B cell infiltrate in murine renal allograft 
tissue. 
B220 immunostaining performed on murine transplanted renal tissue 
harvested at day 7. Isograft FVB→FVB (n=5). Allograft Balbc→FVB 
(n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
There is significant infiltration of B cells in the cortex p<0.001*** 
and medulla p<0.05* of allografts compared to the isografts. This B 









Figure 5- 7 Blood analysis of circulating mononuclear cells at 
day 7 post transplant using flow cytometry. 
Venous blood was collected from the murine recipients at the time of 
termination of the experiment on day 7 post transplant. Peripheral 
blood leukocytes were prepared, immunolabelled and assessed by 
flow cytometry. 
A Significant reduction in the number of circulating monocytes in the 
DT treated CD11b-DTR mice compared to FVB control mice p<0.05*. 
B Significant reduction in the number of circulating B cells in the DT 
treated CD11b-DTR mice compared to FVB control mice p<0.05*. 
C & D No difference in the number of circulating T cells (CD4 & CD8) 
in the DT treated CD11-bDTR mice compared to the FVB control 
mice.  








5.4  Reduction in microvascularity seen in murine 
allografts is inhibited by macrophage depletion 
Peritubular capillaries (PTC) identified by CD31 immunostaining were 
present in the isografts. In the allograft there was evidence of loss of 
PTCs with preservation being seen following Mφ depletion (fig 5-8). 
Quantifying these observations and expressing our findings as the 
mean number of peritubular capillaries per 100 tubules (Ohashi et 
al., 2002) the allografts were found to have a significantly reduced 
microvascularity in both the cortex and medulla compared to the 
isograft; cortex (64.97±7.28 vs 130±10 control allograft vs isograft; 
p=0.002), medulla (70.5±6.9 vs 127±7.3, control allograft vs 
isograft; p=0.002). Preservation of the microvasculature was 
achieved with Mφ depletion and significantly more PTCs were seen in 
this group compared to the allografts. Numbers  of PTC seen in this 
Mφ depleted group were in fact comparable to those seen in the 




Figure 5- 8 Allograft exhibit a reduction in CD31 
microvascularity, which is preserved following DT, mediated 
monocyte/Mφ ablation. 
CD31 immunostaining performed on murine transplanted renal 
tissue harvested at day 7. Isograft FVB→FVB (n=5). Allograft 
Balbc→FVB (n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
A Peritubular capillaries are visible in the isograft tissue (example 
arrowed). 
B Destruction and loss of peritubular capillaries are evident in the 
allograft. 
C Preservation of peritubular capillaries is evident following DT 







Figure 5- 9 Diphtheria toxin mediated monocyte/Mφ ablation 
preserves microvasculature in murine renal allograft tissue. 
CD31 immunostaining performed on murine transplanted renal 
tissue harvested at day 7. Isograft FVB→FVB (n=5). Allograft 
Balbc→FVB (n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
There is significant loss of peritubular capillaries (PTC) in the cortex 
and medulla of allografts compared to the isografts p<0.01**. This 








5.5  Reduction in tubular iNOS expression and 
increased interstitial iNOS expression is seen in 
murine allografts. 
Isografts appeared to express high levels of iNOS within all tubules 
with very little being seen within the interstitium. In contrast 
allografts showed high levels of interstitial iNOS expression and loss 
of tubular iNOS expression. In the Mφ depleted group there appeared 
to be preservation of tubular iNOS expression with a reduction in 
interstitial iNOS expression (fig 5-10). 
Quantifying these observations and expressing the findings as the 
mean number of iNOS positive cells per 25-point graticle, isografts 
exhibited almost negligible interstitial iNOS expression, which is 
significantly increased in the allografts (0.07±0.046 vs 5.03±0.33 per 
25 point graticle, isograft vs allograft; p<0.001). Mφ depleted 
allografts express significantly less interstitial iNOS compared to the 
control allograft (2.5±0.33 vs 5.03±0.33 per 25 point graticle, Mφ 
depleted vs control allograft; p<0.001) (fig 5-11A). 
Expression of tubular iNOS was quantified and expressed as the 
mean number of iNOS positive tubules per 25-point graticle. The 
isografts expressed significantly higher levels of this tubular iNOS 
compared to allografts (8.1±1.03 vs 1.84±0.3 per 25 point graticle 
isograft vs allograft; p<0.001). Although there was a non-significant 
trend towards preservation of tubular iNOS expression following 
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Mφ depletion, there was still significantly less expression to that seen 
in the isografts  (fig 5-11B) 
 
5.6  Urine nitrite concentrations are comparable pre 
and post transplantation and are unaffected by Mφ 
depletion 
Urine nitrite concentrations were analysed using Griess assay and 
corrected for urine concentration by expressing the data as the urine 
nitrite concentration/creatinine ratio. Urine samples were taken by 
direct bladder puncture in both the allograft group and the Mφ 
depletion group pre transplant and at day 7 post transplant at the 
time of sacrifice. This demonstrated no difference in nitrite 
concentrations pre and post transplant or between allograft and 
Mφ depleted groups (fig 5-12). 
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Figure 5- 10 iNOS immunostaining on murine transplanted 
renal tissue. 
Isograft FVB→FVB (n=5). Allograft Balbc→FVB (n=18). Mφ depleted 
CD11b-Balbc→DTR (n=10). 
A Isografts exhibit tubular expression (example black arrowed) of 
iNOS with a very low level of interstitial expression. B Allografts 
exhibit increased interstitial iNOS expression (example yellow arrow) 
and reduced tubular iNOS expression compared to isografts 
(example black arrow) C Mφ depletion inhibits interstitial iNOS 




Figure 5- 11 Allografts exhibit increased interstitial iNOS 
expression and reduced tubular expression of iNOS compared 
to isografts. 
iNOS immunostaining performed on murine transplanted renal 
tissue. Isograft FVB→FVB (n=5). Allograft Balbc→FVB (n=18). Mφ 
depleted Balbc→DTR (n=10). 
A There is a significant increase of interstitial iNOS expression in 
allografts compared to the isografts p<0.001***. This is inhibited by 
Mφ depletion p<0.001*** 
B There is significant loss of tubular iNOS expression in allografts 





Figure 5- 12 Urine nitrite concentration is not affected by Mφ 
depletion. 
Urine was collected pre transplant and at day 7 post transplant in 
both the allograft and Mφ depleted models. This was analysed for 
nitrite concentration using a Griess assay and corrected for 
creatinine concentration. No difference in nitrite concentration was 
seen following transplantation either within groups or between the 













5.7  Lymphatic vessels in murine transplanted renal 
tissue 
In the isografts, discrete podoplanin positive lymphatic vessels were 
positioned around intrarenal arteries. In the allograft in addition to 
these discrete lymphatic profiles there was also a reticular network 
of podoplanin positive channels not yet clearly defined as vessels 
spreading out from the perivascular region. This was not seen in the 
isograft and was reduced in the Mφ depleted allografts (fig 5-13). 
The numbers of podoplanin positive vessels were expressed as the 
mean number of discrete podoplanin positive vessels, which were 
circular and had a visible lumen per intra renal artery. In the 
allograft there was a significant increase in these fully formed 
lymphatics compared to the isografts (4.7±0.42 vs 2.5±0.2 lymphatic 
vessels/arterial profile, allograft vs isograft; p<0.001). In the 
Mφ depleted allograft the lymphatic vessel number was reduced to 
levels comparable to those seen in the isograft (2.2±0.33 vs 2.5±0.2 
lymphatic vessels/arterial profile, Mφ depleted vs isograft), which is 
significantly reduced, compared to the allograft (fig 5-14) 
An additional interesting observation was that in the allograft tissue 
some of these new well defined lymphatics appeared functional as 
they contained an abundance of cells within their lumen including 
mononuclear cells with ingested apoptotic cells. This was not seen in 





Figure 5- 13 Podoplanin positive vessels in murine 
transplanted renal tissue. 
Podoplanin immunostaining was performed on murine transplanted 
renal tissue harvested at day 7. Isograft FVB→FVB (n=5). Allograft 
Balbc→FVB (n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
A Isografts exhibit a normal number of well defined perivascular 
lymphatic vessels (example arrowed). 
B Allografts develop a reticular network of developing podoplanin 
positive lymphatics (example arrowed).  
C DT mediated monocyte/Mφ ablation treatment inhibits the 






Figure 5- 14  The increased number of lymphatic venules 
evident in allografts is inhibited following Mφ depletion. 
Podoplanin immunostaining was performed on murine transplanted 
renal tissue harvested at day 7. Isograft FVB→FVB (n=5). Allograft 
Balbc→FVB (n=18). Mφ depleted Balbc→CD11b-DTR (n=10). 
There is a significant increase in lymphatic vessels in allografts 
(p<0.01**) compared to the isografts (p<0.05*). This is 










Figure 5- 15 Mφ containing an ingested apoptotic cell within a 
podoplanin positive lymphatic vessel arrowed). 
Murine renal allograft Balb→FVB harvested at day 7 and 
immunostained for podoplanin lymphatic marker.  
(x400 magnification) 
Within the podoplanin +ve vessels are both Mφ containing apoptotic 
cells, as well as numerous other cells, which implies functionality of 
these podoplanin +ve vessels. 
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5.8 Summary & discussion 
To summarise, a reduction in interstitial microvascularity in the 
allograft compared to the isograft controls was found associated with 
increased interstitial iNOS expression. In addition, there was an 
increase in lymphatic vessel number in the perivascular region. All 
these changes were inhibited following Mφ depletion. 
In this thesis all the data was carried out on the model of acute 
rejection in which the recipient retained a native functioning kidney 
and therefore graft function cannot be determined.  
In this model a loss of tubular iNOS expression was demonstrated 
which was previously suggested as being protective (Du et al., 2006)  
and an increase in interstitial iNOS expression, thought to be 
detrimental was evident in the allograft compared to the isograft. 
Mφ depletion significantly reduced interstitial iNOS expression 
compared to the allograft and although there was a non-significant 
trend towards preservation of tubular iNOS expression following 
Mφ depletion, there was still significantly less expression to that seen 
in the isografts.  
Interestingly there was significant inhibition of tubular iNOS 
expression in the allograft compared to the isograft. Recent work 
suggests that endogenous iNOS expression by tubular cells at low 
concentrations has a protective role in renal grafts and therefore 
these findings that tubular expression is reduced in the allograft 
where microvascular loss is seen is consistent with this. 
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This finding of significant tubular iNOS expression in the isograft, 
which then appears to be inhibited and replaced, by interstitial 
expression may explain the urine nitrite findings in this model. 
Previous studies have demonstrated increased urinary nitrite in 
rejecting grafts compared to those who continue to enjoy stable 
function (Smith et al., 1996). In these studies no difference was 
found between pre and postoperative concentrations when corrected 
for creatinine concentration within groups or between the two 
groups. I speculate that this is due to a significant loss of tubular 
iNOS expression at the same time as there is an increased interstitial 
expression and therefore the overall nitrite produced remains 
constant i.e. comparable amounts of NO continue to be produced but 
the source varies i.e. from tubular to interstitial with tubular NO 
generation being predominant in isografts and interstitial NO 
generation being predominant in allografts. 
In the isograft there is generally less interstitial infiltrate, which 
mirrors the low interstitial iNOS expression. 
Using immunostaining renal tubules are seen to produce iNOS, which 
is reduced in the allograft, this may be due to the tubular epithelial 
destruction, or there is down regulation of tubular iNOS expression 
in the allograft compared to the isografts. 
Despite evidence of a new network of lymphatics spreading out 
towards the interstitium no well defined lymphatic vessels were seen 
in the interstitium: unlike the human CAN tissue. This may be 
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because the murine model is looking at acute rejection whereas the 
human tissue is CAN and so we may be seeing the process at a 
much earlier time point. Alternatively the pattern may vary between 
species.  
The reticular network of podoplanin stain seen in the murine 
allograft may be immature lymphatics forming. Alternatively it may 
be that infiltrating Mφ may express podoplanin since Mφ have been 
documented to transdifferentiate to LEC. Double staining with F4/80 
and podoplanin would be informative as would an additional LEC 
marker. 
Could all the changes observed in the murine model be purely due to 
non-specific inflammation or are the changes specific to graft 
rejection? It does not appear to be just a response to renal IRI 
because the isograft has presumably endured a comparable degree 
of IRI as the allograft. Thus the mononuclear cell infiltrate, loss of 
microvasculature and increased lymphatic number are specific to 
graft rejection. 
We found a significant interstitial infiltrate of both B and T cells in 
the allograft compared to the isograft and importantly this infiltration 
was not attenuated by DT treatment. Examining the blood of these 
mice at day 7 there was a reduction in CD11b/GR1+ and GR1-
monocytes. No change was found in circulating T cells supporting our 
findings in the renal tissue, however there was a significant 
reduction in circulating B cells not seen in the tissues. We know B 
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cells may express CD11b. We also know that other forms of 
Mφ ablation such as clodronate can also have an effect on lymphoid 
cells. We could use these differences to our advantage in the future 
to tease out mechanisms. In addition we could carry out pure B cell 
depletion using the murine antibody similar to Rituximab to study 
the role of B cells in rejection. 
Further work looking at the effect of DT treatment on the dendritic 
cell (DC) population was carried out in the laboratory after I had 
completed my research period. It was found that CD11C+ DC 
infiltration was reduced in the renal allograft which would be 
expected as GR1+ monocytes differentiate into DCs in the tissue, 
therefore if you knock out all monocytes within the circulation this 
will result in a reduction of cells available to develop into DCs. 
Importantly it was found that there was no reduction in splenic 
CD11c+ cells following DT treatment. 
 
Consultant Renal pathologist Dr Chris Bellamy assessed the severity 
of acute rejection in the renal sections. He found only mild 
inflammation in the isografts, evidence of both cellular and vascular 
rejection in the allografts with a trend towards reduction in both 









Chapter 6.  
 
Lymphatic phenotyping 
and isolation in vitro  
 
 173
6.1  Background  
The studies outlined in previous chapters on both human and murine 
tissue using immunostaining demonstrated the existence of two 
endothelial cell populations: vascular and lymphatic. Studies in 
human CAN and a murine model of acute rejection, demonstrate 
that these two populations appear to respond differently to the 
process of CAN and acute rejection since in the presence of a Mφ 
infiltrate the microvessels undergo destruction whilst lymphatic 
vessels increase in number. The in vitro work described further 
investigated the effect of the cytokine activated Mφ on a population 
of endothelial cells and observed an increase in apoptosis of these 
cells. 
The logical next step was to study the effect of the Mφ on the 
lymphatic endothelial cell in vitro to examine any differences in 
response that may occur to that seen with the MCEC-1 cells. 
For these studies to be undertaken a pure population of LECs was  
first required. The following chapter describes attempts to isolate 








6.2  Human umbilical vein endothelial cells (HUVECs) 
contain a small proportion of lymphatic endothelial 
cells. 
Using flow cytometry studies confirmed that HUVECs  were  positive 
for the endothelial cell marker CD31. Staining with the lymphatic 
endothelial cell marker VEGFR-3 revealed that HUVECS also 
contained a small subpopulation of cells that were VEGFR-3+  
(11.75%) (fig 6-1) 
Further phenotyping using immunofluorescence confirmed that these 




Figure 6- 1 Phenotyping HUVECs using flow cytometry 
HUVECs were stained with the lymphatic endothelial cell marker 
VEGFR-3 with the secondary conjugated to Alexa 488. The level of 
expression was analysed using flow cytometry. 
A the dot plot shows the total cell population 
Histograms of control groups B Cells alone C VEGFR-3 secondary 
antibody alone +488 D VEGFR-3 isotype control +488. 
E VEGFR-3-488 staining; histogram shows a discrete population 







Figure 6- 2 Phenotyping HUVECs using immunofluorescence 
HUVECs were prepared and labelled with VEGFR-3 and secondary 
antibody conjugated with Alexa 488. Analysis using fluorescent 
microscopy revealed some VEGFR-3-FITC (green) HUVECs. 
Controls including cells alone, secondary alone (goat anti rabbit-488) 
and Rabbit IgG isotype control confirmed that non specific staining 











6.3  Human dermal microvasular endothelial primary 
cells (HUDMECS) are made up of lymphatic and 
vascular endothelial cell populations. 
Using flow cytometry, HUDMECs  were confirmed to be positive  for 
the endothelial cell marker CD31. Double staining with CD31 and the 
lymphatic endothelial cell marker podoplanin revealed that these 
cells were made up of two populations CD31+/Podoplanin- cells 
(43.3%) and CD31+/podoplanin+ cells (56.7%) (fig 6-3). 
Further phenotyping using immunofluorescence revealed that these 
HUVECs did indeed have a population of VEGFR-3+ cells (fig 6-4) 
No further investigations were carried out on these primary cells as 
despite the claims of the manufactures they were extremely difficult 
to passage making it impossible to expand the cell culture in order to 






Figure 6- 3 Phenotyping HUDMECs (cell line) using flow 
cytometry 
HUDMECs were stained with the endothelial cell marker CD31 
conjugated to PE and lymphatic endothelial cell marker podoplanin 
conjugated to Alexa 488. The level of expression was analysed using 
flow cytometry. Dot plots A CD31 stain all cells seen in the left upper 
quadrant. B CD31 isotype control no shift seen. C Podoplanin stain 
two populations seen, one population does not shift the other shifts 
to the right lower quadrant. D Podoplanin isotype control no shift 
seen. E Double stain CD31 and podoplanin, two populations seen 
one in the right upper quadrant and one in the left upper quadrant.  
F Histogram confirms two populations;  








Figure 6- 4 Phenotyping HUDMECs (primary cells) using 
immunofluorescence. 
HUDMECs were prepared and labelled with VEGFR-3 and secondary 
antibody conjugated with Alexa 488 (green). Analysis using 
fluorescent microscopy revealed VEGF-3-488 positive cells (green) 
Controls; cells alone, isotype control and secondary antibody alone 
showed no staining. (x320 magnification) 
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6.4  Human dermal microvasular endothelial cell Line 
(HUDMECS) 
A population of podoplanin positive HUDMECs was isolated using 
magnetic bead sorting. This population was successfully cultured (fig 
6-5), and then phenotyped. Flow cytometry revealed that this 
population of HUDMECs which were 92.9% CD31+/podoplanin+ (fig 
6-6). Electron microscopy studies revealed that this population of 
cells were non descript in ultrastructural terms with no Weibel Palade 
bodies and no other features such as caveolae, microvilli or 




   x200                                                  x400 
Figure 6- 5 HUDMECs were cultured following magnetic bead 
sorting for CD31+/podoplanin+ cells 
Following magnetic bead sorting the cells were plated onto 48 well 
plates in endothelial cell medium and cultured at 370C. After 24 
hours they were analysed using light microscopy. The cells were 
seen to have plated down successfully and a cobble stone 




Figure 6- 6 Phenotyping HUDMECs (cell line) post magnetic 
bead sort using flow cytometry. 
Following positive selection for CD31+/podoplanin+ cells using 
magnetic bead sorting the HDMECs were stained with the endothelial 
cell marker CD31 conjugated to PE and lymphatic endothelial cell 
marker podoplanin conjugated to Alexa 488. The level of expression 
was analysed using flow cytometry dot plots; A CD31 stain all cells 
seen in left upper quadrant. B CD31 isotype control no shift seen. C 
Podoplanin stain population seen in right lower quadrant. D  
Podoplanin isotype control; no shift seen. E Double stain CD31 and 










Figure 6- 7 Electron microscopy of HUDMECs (cell line) after 





6.5  Summary & discussion 
The aim of this work was to obtain a pure population of human 
lymphatic endothelial cells, which could then be used in co-culture 
experiments with human Mφ. Our prediction being that we would 
observe increased proliferation, increased cell number and no 
apoptosis. 
These studies were limited by various problems. Initial studies 
looked at HUVECs. We know from the literature that passaging 
vascular endothelial cells can induce transdifferentiation into 
lymphatic endothelial cells (Groger et al., 2004). Our studies 
supported this by finding VEGFR-3 positive cells, but as expected 
this made up only a small proportion of the cell population 11.75%. 
This was therefore not a feasible source for future studies. 
Further experiments used primary HUDMECs produced commercially 
from Promocell. Despite demonstrating that 50% of these cells were 
made up of Podoplanin positive endothelial cells these cells were 
difficult to use.  There were problems with infection and the cells 
were only viable up to passage 3, which made them potentially 
expensive. 
Later experiments used a cell line given to us as a gift from the 
Centre for Disease Control and Prevention, Atlanta, Georgia. These 
HUDMECs were more amenable to studies. There were no infection 
problems and they could be passaged up to P9. Studies 
demonstrated a large population of podoplanin positive endothelial 
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cells and these were sorted using magnetic beads. These sorted cells 
appeared to survive well in culture. Electron microscopy of these 
sorted cells revealed very non-specific structures with no 
ultrastructural features of vascular endothelial cells.  
Further phenotyping using alternative LEC markers is necessary 










Chapter 7.  
 
            Discussion 
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7.1 General Discussion 
Introduction 
Renal transplantation is the treatment of choice for patients with end 
stage renal failure. One of the main obstacles facing the transplant 
community is graft rejection. The development of effective treatment 
strategies to combat T cell mediated injury have significantly 
reduced the incidence of acute rejection with graft survival rates now 
reaching over 90% at 1 year following transplantation. Unfortunately 
rejection episodes can still complicate the early post-transplant 
period resulting in both early graft failure or acting as a significant 
risk factor for the development of late graft failure. Indeed chronic 
rejection and long term graft survival rates remain problematic with 
no effective treatment options currently available. There is still 
controversy and flux over the nomenclature in this area. CAN 
replaced the term chronic rejection in 1991 (Solez et al., 1993) and 
helped to address the misconception that late scarring of the graft 
was only due to alloimmune injury. There have now been thousands 
of Pubmed citations using the term CAN. However the most recent 
Banff conference (July 2005) decided to discontinue use of this term 
due to the misconception that CAN is a specific disease entity rather 
than a term for non-specific fibrosis. The term CAN has now been 
replaced by the following description Interstitial fibrosis and tubular 
atrophy, no evidence of any specific aetiology (Solez k, Am J T 
2007). However for the purposes of this thesis I will continue to use 
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the term CAN as this was the term in use when these studies 
commenced. 
 
Much of the focus in the last 15-20 years has been on the adaptive 
immune response with T cells being the main focus of interest. There 
is however evidence to suggest that the innate immune response 
plays a significant role in the process of allograft rejection (Land, 
2007; LaRosa et al., 2007) and the work outlined in this thesis has 
focussed on the Mφ and endothelial cells.  The Mφ is a versatile cell 
and performs diverse functions ranging from phagocytosis to antigen 
presentation. Mφ are involved in the inflammatory response to injury 
or infection, tissue repair and importantly are key to both the innate 
and acquired immune response. Previously published studies indicate 
that Mφ are involved in both acute and chronic rejection of the 
kidney and other organs (Croker et al., 1996; Jose et al., 2003; 
Ozdemir et al., 2002; Pilmore et al., 2000; Szabolcs et al., 1996). In 
addition, more recent studies have suggested a role for Mφ in the 
lymphangiogenesis that may be evident in renal allograft rejection 
(Kerjaschki et al., 2004), tumour development (Schoppmann et al., 
2002) and other inflammatory states (Pepper et al., 2003; Skobe et 
al., 2001). 
 
The focus of this work has been the innate immune response with an 
emphasis upon the effect of the Mφ on both the vascular and 
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lymphatic endothelial cell populations in the context of both CAN 
(human studies) and acute rejection (murine studies). In addition, in 
vitro studies were employed to gain mechanistic insight into the 
cytotoxic action of Mφ  upon vascular endothelial cells. This thesis set 
out to investigate the hypothesis that Mφ are directly responsible for 
VEC death through the production of various death effectors such as 
NO but play a key role in rejection associated lymphangiogenesis 
through the expression of lymphangiogenic growth factors such as 
VEGF-C. In this chapter I shall outline the key findings of my studies 
and suggest additional work that may be undertaken to further 
define the role of Mφ in the acute and chronic complications of renal 
transplantation.  
 
SUMMARY OF KEY FINDINGS 
Mφ and CAN in human transplant nephrectomies 
Human tissue from transplant nephrectomies performed because of 
CAN were studied and compared to control kidney tissue obtained 
from nephrectomy specimens performed for renal tumours. Previous 
work from the laboratory demonstrated a reduction in the number of 
CD31+ PTC in human CAN tissue compared to controls (Adair et al., 
2007). This reduction in PTC number was associated with an 
increased interstitial Mφ infiltrate in the CAN tissue with a sub-
population of interstitial Mφ expressing iNOS. No obvious reduction in 
tubular expression of VEGF-A was evident whilst B cells exhibited 
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significant VEGF-A expression. Furthermore, CAN tissue exhibited 
interstitial lymphatic vessels that were not evident in control tissue 
with occasional CD68+ Mφ expressing VEGF-C.  
 
Mφ, PTC rarefaction and lymphangiogenesis in experimental murine 
allograft rejection  
In the murine model of acute rejection IHC studies demonstrated an 
increase in interstitial Mφ infiltration in the allograft associated with a 
significant reduction in the number of PTC. Also, increased interstitial 
iNOS expression was evident compared to the isograft. Mφ ablation 
undertaken from day 3 in this model was protective and inhibited the 
loss of PTC with PTC number in the Mφ ablated group being 
comparable to that of isograft controls. In addition, Mφ ablation was 
associated with reduced interstitial iNOS expression. This murine 
model of acute renal rejection also demonstrated a significant 
increase in the number of podoplanin+ perivascular lymphatic vessels 
compared to isograft controls with this increase being prevented by 
Mφ ablation. In addition, a reticular podoplanin+ network was noted. 
 
In vitro studies of Mφ and endothelial cells  
Co-cultures of murine Mφ  (BMDM) and vascular endothelial cells 
were used to examine the cytotoxic mechanisms employed by 
cytokine activated Mφ in the induction of endothelial cell death. 
Significant levels of apoptosis of murine endothelial cells was evident 
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in co-cultures with cytokine activated BMDM (LPS and IFN−γ). In 
contrast, Mφ-mediated endothelial cell proliferation was inhibited by 
both cytokine-activated and control non-activated Mφ. Mφ-induced 
apoptosis was effectively inhibited by blocking the action of the 
enzyme iNOS thereby supporting a key role for NO in this system. 
Furthermore, iNOS blockade of cytokine-activated Mφ did not affect 
the marked production of TNFα by these inflammatory cells. Lastly, 
in somewhat preliminary work, the use of LEC markers (podoplanin 
and VEGFR-3) indicated that human cell populations viewed as 
vascular endothelial cells (primary HUVECs and the HDMEC cell 
line) actually consist of a mixture of vascular and lymphatic 
endothelial cells as a distinct population of podoplanin+/CD31+ cells 
was demonstrated by flow cytometry. Also, immunomagnetic bead 
sorting of mixed cell populations produced a >90% 
podoplanin+/CD31+ cell population that was successfully plated and 
cultured with EM studies demonstrating cells with no ultrastructural 
features of vascular endothelial cells. 
 
Discussion 
There is still controversy in the literature as to whether increased 
angiogenesis or loss of microvasculature occurs during renal disease 
and renal allograft rejection. Ozdemir et al. demonstrated increased 
angiogenesis associated with increased VEGF-A expression by 
infiltrating Mφ, which increased the risk of graft loss (Ozdemir et al., 
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2002). However Ishii et al. demonstrated loss of PTC which 
correlated with both the severity of CAN and loss of graft function 
(Ishii et al., 2005). Work by Kang et al. and Ohashi et al. in rat and 
murine models of renal disease respectively also demonstrated PTC 
loss in native kidneys following the induction of renal inflammation 
and scarring with PTC loss being associated with reduced 
endogenous expression of VEGF-A and Mφ infiltration (Kang et al., 
2001a; Kang et al., 2001b; Ohashi et al., 2002).  
 
Our work demonstrated a loss of the peritubular microvasculature in 
human tissue affected by CAN as well as murine renal allografts 
exhibiting rejection with both human and murine tissue exhibiting 
significant Mφ infiltration. In human CAN tissue, interstitial VEGF-A 
expression was demonstrated but double labelling studies indicated 
that VEGF-A was not expressed by infiltrating Mφ as seen by Ozdemir 
et al. but was prominently expressed by B cells. Since the 
angiogenesis described by Ozdemir et al. was based upon use of the 
endothelial marker CD31 that may be expressed by vascular and 
lymphatic endothelial cells, it is possible that the angiogenesis 
evident reflected the net effect of an increase in LEC number and a 
reduced VEC number (Matsui et al., 2003; Ozdemir et al., 2002). 
However, this is not the case in the work described in this thesis 
which also used the endothelial cell marker CD31 as a reduced 
number of CD31+ vessels was demonstrated despite the presence of 
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increased numbers of interstitial lymphatic vessels demonstrated 
using the LEC marker podoplanin. 
 
It may well be the case that in the early stages of tissue injury there 
is an increase in VEC number associated with increased vascular 
endothelial cell proliferation secondary to increased VEGF-A 
production by the local tissues as a response to hypoxia (Pilmore et 
al., 1999). However, as the injurious process continues and tissue 
destruction overrides the reparative response there will be a 
reduction in the tissue available to produce the angiogenic factors. In 
addition, microvascular loss may be promoted by the increased 
influx of Mφ that can indirectly inhibit VEGF-A production from 
resident renal cells (Kang et al., 2001a; Kang et al., 2001b) and are 
directly cytotoxic to the endothelium.  
 
Our finding that B cells exhibit marked expression of VEGF-A in 
human kidney tissue affected by CAN is of interest as recent work 
suggests that B cells expressing VEGF-A are important in 
lymphangiogenesis (Angeli et al., 2006) and VEGF-A is implicated in 
both angiogenesis and lymphangiogenesis. For example, Cursiefen et 
al. demonstrated that Mφ are key players in the haemangiogenesis 
associated with ocular inflammation as they are the only source of 
VEGF-A (Cursiefen et al., 2004). In contrast, parenchymal cells of 
the kidney i.e. podocytes and tubular cells express VEGF-A and 
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angiogenesis may be reduced during renal inflammation as a result 
of Mφmediated inhibition of VEGF-A expression (Kang et al., 2002; 
Masuda et al., 2001; Ohashi et al., 2000; Ohashi et al., 2002). 
It is important to note, however, that kidneys affected by CAN 
exhibited reduced PTC numbers despite the presence of B cells 
expressing VEGF-A.  
 
The situation is undoubtedly complex as Mφ undoubtedly exist as a 
heterogeneous population within tissues with both pro-inflammatory 
and anti-inflammatory Mφ being present at the same time. In 
addition, Mφ may be pro-angiogenic and anti-angiogenic (Ozdemir et 
al., 2005; Pilmore et al., 1999) whilst Mφ phenotype may also 
change over time as the disease process progresses due to the 
effects of various different stimuli such as hypoxia, cytokines, 
apoptotic cells etc. The conflicting findings that are present within 
the published literature may also reflect the kinetics of the disease 
process with angiogenesis occurring at early time points followed by 
microvascular rarefaction that becomes increasingly evident in the 
long term. 
  
There has been limited study of lymphatic vessels in the context of 
renal transplantation. Although previous studies examining the 
restoration of the lymphatic drainage of autotransplanted limbs in a 
rat model indicated that lymphatic flow is restored but may follow a 
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more superficial route (Smaropoulos et al., 2005). In fact interest in 
lymphatics is relatively new and there is debate as to whether the 
process of lymphangiogenesis in the transplanted organ is inherently 
good or bad. In the murine model we observed that lymphatic 
vessels contained Mφ which had ingested apoptotic cells in addition 
to T and B lymphocytes. Although this observation certainly supports 
the theory that these lymphatic vessels are an important exit conduit 
for the inflammatory infiltrate, it does not indicate that the lymphatic 
system is completely reconnected. If the development of new 
lymphatic vessels is key to the clearance of the inflammatory 
infiltrate from the kidney then this may be beneficial or detrimental. 
For example, the clearance of injurious cells such as activated Mφ 
and cytotoxic T cells is likely to be beneficial and contribute to the 
resolution of the inflammatory process. In contrast, the facilitation of 
the trafficking of APCs such as dendritic cells to the lymph nodes 
may well stimulate the adaptive immune system to continue the 
alloimmune response against the graft. 
 
We often observed nodular infiltrates of B cells and T cells in the 
proximity of new lymphatics. Kerjaschki et al reported the presence 
of nodular infiltrates in a subset of acute rejection tissue with the 
infiltrates containing B cells, T cells and CCR7+ cells whilst the 
lymphatic vessels expressed CCL21 which is the ligand for CCR7 
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(Kerjaschki et al., 2004). These nodular infiltrates resemble tertiary 
lymphatic structures that perpetuate immune responses. 
 
The presence of the B cell is of much interest as recent work 
suggests that B cells may play an important role in the process of 
lymphangiogenesis. B cells are present in the tissue of renal grafts 
undergoing both acute and chronic rejection and are not evident in 
normal renal tissue (Martins et al., 2007). Angeli et al. noted that B 
cell expression of VEGF-A is central to the lymphangiogenesis 
associated with expansion of lymph nodes (Angeli et al., 2006). 
Cursiefen et al. also noted a key role for VEGF-A in the 
haemangiogenesis and lymphangiogenesis present in the inflamed 
rodent eye although the Mφ was the key cell in this situation 
(Cursiefen et al., 2002). In the context of acute renal allograft 
rejection it is interesting to speculate that VEGF-A expression by B 
cells may be partly responsible for Mφ recruitment and subsequent 









7.2 Future work 
Although these studies have provided significant insights into the 
interaction that may occur between Mφ and endothelial cells, there 
are still many questions that remain unanswered and much further 
work is required before a complete picture emerges.  
 
Human Tissue Studies 
The study of the human renal tissue available to us provided 
pathological information about Mφ infiltration and the peritubular and 
lymphatic vessels in CAN. It would therefore be informative to study 
the microvasculature (PTC number and endothelial proliferation), Mφ 
and lymphocyte infiltration and VEGF-A expression of serial biopsies 
from patients undergoing renal transplantation such that the kinetics 
of these processes may be determined. In addition, the study and 
quantification of lymphatic vessels, VEGF-C expression etc in these 
biopsies would also shed light upon the kinetics of the development 
of interstitial lymphatic vessels following transplantation. Also, it 
would be informative to study these same parameters in biopsies 
from a group of well functioning renal allografts that have been in 
situ for a comparable length of time as the kidneys affected by CAN. 
This would indicate whether changes in the number of PTC and 
lymphatic vessels are found in all transplanted kidneys in the 
absence of CAN and simply reflect changes that occur over time in 
the absence of overt pathological disease. 
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In CAN tissue, unlike control tissue, interstitial Mφ express iNOS and 
it would be interesting to undertake triple immunostaining for Mφ, 
iNOS and VEGF-C to determine if the same population of Mf may be 
responsible for both VEC death and LEC proliferation. Since 
heterogeneous populations of Mφ exist within tissues, it may be the 
case that there are phenotypically distinct groups of Mφ that are 
responsible for the PTC and lymphatic changes that occur during the 
development of CAN. Alternatively, the combination of double 
labelling for Mφ  and VEGF-C and iNOS and VEGF-C double labelling 
would also provide similar information. For example, if VEGF-C 
consistently localised to Mφ  but never co-localised with iNOS then 
this would indicate that the presence of distinct Mφ populations.  
 
It would also be important to examine the correlation of the changes 
observed in the potential future experiments outlined with transplant 




The work presented in this thesis implicates Mφ-derived NO in the 
deleterious PTC rarefaction evident in the acute rejection of a murine 
renal allograft but the data is not definitive. Further work should 
include examining the specific effect of iNOS blockade upon acute 
rejection and PTC attrition in the murine transplant model with the 
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prediction that microvascular damage would be ameliorated by iNOS 
blockade. This could be achieved by administering the iNOS-specific 
inhibitor L-Nil (control DNil) in the drinking water (Kipari et al., 
2006). An alternative strategy to dissect the role in iNOS would be to 
transplant kidneys from an iNOS wild-type mouse to an iNOS 
knockout mouse but this approach is unfortunately complicated by 
the murine strain requirements of the transplant model (iNOS 
knockout mice of the FVB/N strain would be required).  
 
Although the in vitro studies did not suggest a role for TNFα or FasL, 
the in vivo environment is significantly more complicated and it 
would be interesting to attempt to block the action of TNFα in vivo 
using function blocking antibodies or soluble receptors. It may be the 
case that TNFα blockade may modulate the phenotype of infiltrating 
Mφ in this model with secondary effects upon the generation of other 
cytotoxic mediators such as NO. 
 
In the transplant model used in these studies, the acute rejection 
process does not adversely affect renal function as the normal left 
kidney is left in situ. The future development of a functional 
transplant model (transplant dependent model) would be of interest. 
In this case, the recipient would undergo a 2nd nephrectomy at day 5 
following the transplant procedure. This model would allow the effect 
of various interventions upon renal function to be determined. 
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In the murine model changes occurring during acute rejection have 
been studied whilst the human tissue studies examined the changes 
occurring during end stage CAN. It would thus be informative to 
establish a murine model of chronic rejection such that the role of 
Mφ  and various Mφderived mediators could be studied in the 
context of chronic rejection. This would facilitate careful time course 
experiments to examine the kinetics of the inflammatory and 
pathological changes and also allow attempts to ameliorate the 
chronic changes by performing interventional studies such as the 
administration of VEGF-A, blockade of iNOS or the administration of 
modified anti-inflammatory Mφ.   
 
Further work is required to determine the exact mechanisms and 
function of the lymphangiogenesis described in the murine transplant 
model. First, however, it will be important to undertake further 
studies with additional lymphatic markers such as VEGFR-3, prox-1 
etc to validate the finding. It would be interesting to perform a 
digital 3D reconstruction after staining multiple sequential tissue 
sections to determine if the new lymphatic network communicates 
with the pre-existing lymphatic system.  
 
At the current time, it is unclear when the lymphatic system of the 
transplanted kidney becomes reconnected and therefore it would be 
of interest to undertake protein and cell tracking experiments in 
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transplants at various time points post-transplantation. For example, 
fluorescent low molecular weight dextran, carbon particles or 
fluorescent T cells could be injected into the renal parenchyma with 
subsequent harvesting of the regional lymph nodes in order to look 
for evidence of trafficking of these particles or cells by microscopy or 
flow cytometry of enzymatically dissociated lymph nodes. These 
studies would shed light upon the time course of restoration of 
lymphatic drainage following the severance of the lymphatic vessels 
at transplantation.  
 
It was not possible to assess the proliferation of either vascular or 
lymphatic endothelial cells using the proliferation marker MIB-1 and 
further work should employ the administration of Brdu prior to 
culling the animal. The role of VEGF-C in the lymphangiogenic 
process needs to be explored further. Immunostaining for VEGF-C 
expression should be undertaken with double labelling studies with 
F4/80 being performed to determine whether the VEGF-C+ cells are 
Mφ. In order to investigate the contribution of lymphangiogenesis to 
the immunological rejection of the allograft the effect of inhibiting 
the action of VEGF-C could be undertaken. Possible strategies may 
employ the administration of functional blocking anti-VEGFR-3 
antibody with readouts including markers of lymphangiogenesis as 
well as the severity of the rejection process. 
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The involvement of B cells in both rejection and lymphangiogenesis 
merits further scrutiny and it would be interesting to determine the 
effect of B cell depletion upon these processes. At the current time, 
however, an anti-murine B cell antibody is not commercially 
available. 
 
In vitro work 
The murine co-culture studies were undertaken using a cardiac 
microvascular endothelial cell line as a renal endothelial cell line was 
not available. Although Mφ often use mediators such as NO to kill 
various cell types including tubular cells, mesangial cells and tumour 
cells, it would be informative to perform similar co-cultures with 
endothelial cells derived from a kidney. Furthermore, interstitial 
endothelial cells rather than glomerular endothelial cells would be 
best as there are differences between these 2 types of intrarenal 
endothelial cells.  
 
It would also be interesting to undertake a series of co-culture 
experiments involving human monocyte-derived Mφ and human 
renal endothelial cells as this would indicate the nature of the death 
effector in a human setting. Previous work has indicated that human 
monocyte-derived Mφ employ NO, TNFα and FasL in the induction of 
death of vascular smooth muscle cells (Boyle et al., 2003) and it is 
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possible that multiple mediators may play a role in the induction of 
apoptosis of human renal endothelial cells.  
 
My preliminary studies suggesting that endothelial cells in culture 
consist of a mixture of vascular and lymphatic endothelial cells 
require additional work to both confirm and extend the findings. If 
the findings are corroborated in extended studies then they have 
important implications for the interpretation of studies using vascular 
endothelial cells and further experiments in this area of endothelial 
cell research. It will be feasible to isolate pure populations of 
lymphatic endothelial cells for direct study and comparison with 
vascular endothelial cells (isolated form the same original mixed 
population). Further and repeated phenotyping of these cells using 
additional LEC markers such as VEGFR3, LYVE-1 and prox-1 would 
be required. Indeed, microarray analysis of the isolated lymphatic 
and vascular endothelial cells would be interesting to perform as 
they should exhibit different gene signatures. Ultimately an attempt 
to perform co-culture studies between Mφ and isolated lymphatic 
endothelial cells could be carried out as previously described using 
the MCEC-1 cells. Also, it would be possible to examine the effect of 
Mφ activated with various stimuli upon a 50/50 mixed population of 
lymphatic and vascular endothelial cells that have been differently 
labelled with fluorescent dyes so that the fate of the lymphatic and 
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vascular endothelial cells in the same co-culture can be separately 
determined. 
 
The in vitro work undertaken in this thesis has utilised 2 dimensional 
cell culture systems. It would be of great interest to develop studies 
in a 3D cell culture system as this would facilitate study of the effect 
of Mφ upon angiogenesis and the 3D structure of lymphatic vessels 
and vascular capillaries. 
  
7.3 Clinical relevance and treatment options 
We need to first understand the mechanisms of the rejection process 
in order to consider realistic targets for treatment. Future work will 
aim to build a comprehensive understanding of the interaction 
between Mφ and vascular and lymphatic endothelial cells in the 
context of renal allograft rejection. Only then can possible treatment 
targets be sensibly considered but future potential translational 
strategies may include: 
• Inhibition of Mφ recruitment to the transplanted kidney 
through the inhibition of key chemokines such as MCP-1. 
• Administration of Mφ  that have been modified ex vivo (e.g. 
treated with cytokines to adopt an alternative activation 
profile) so that they adopt a reparative or anti-inflammatory 
phenotype.  
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• Administration of cytokines (e.g. IL-4, IL-10) systemically 
with the aim of reprogramming the phenotype of Mφ within 
the allograft to a reparative or anti-inflammatory 
phenotype.  
• Modulation of key intracellular signalling pathways such as 
the NFkβ pathway that is a central regulator of pro-
inflammatory gene expression. This may result in increased 
production of anti-inflammatory cytokines such as IL-10. 
• Blockade of key pro-inflammatory cytokines such as TNFα, 
iNOS etc.  
• Administration of mitogens or survival factors such as 
VEGF-A to support the integrity of renal vascular endothelial 
cells. The additional effects of mediators such as VEGF-A 
will need to be carefully considered. 
• Modulation of B cell numbers using the B cell depleting 
antibody Rituximab. 
 
Since both acute rejection and CAN are the result of multiple 
pathophysiological causes of injury it is likely that there will be no 
single magic bullet but that several or combined therapies will be 
needed. Furthermore, such novel therapies will need to be 
incorporated into the current immunosuppressant drug regimens in 
use and ideally tailored to the requirements of the individual patient. 
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